       
 
 
 
 
                                                   
 
University of Dundee
Genome-Wide and Abdominal MRI-Imaging Data Provides Evidence that a Genetically
Determined Favourable Adiposity Phenotype is Characterized by Lower Ectopic Liver
Fat and Lower Risk of Type 2 Diabetes, Heart Disease and Hypertension
Ji, Yingjie; Yiorkas, Andrianos M.; Frau, Francesca; Mook-Kanamori, Dennis; Staiger, Harald;
Thomas, E. Louise; Atabaki-Pasdar, Naeimeh; Campbell, Archie; Tyrrell, Jessica; Jones,
Samuel E.; Beaumont, Robin N.; Wood, Andrew R.; Tuke, Marcus A.; Ruth, Katherine S.;
Mahajan, Anubha; Murray, Anna; Freathy, Rachel M.; Weedon, Michael N.; Hattersley,
Andrew T.; Hayward, Caroline; Machann, Jürgen; Häring, Hans-Ulrich; Franks, Paul; de
Mutsert, Renée; Pearson, Ewan; Stefan, Norbert; Frayling, Timothy M.; Allebrandt, Karla V.;
Bell, Jimmy D.; Blakemore, Alexandra I.; Yaghootkar, Hanieh
Published in:
Diabetes
DOI:
10.2337/db18-0708
Publication date:
2019
Document Version
Peer reviewed version
Link to publication in Discovery Research Portal
Citation for published version (APA):
Ji, Y., Yiorkas, A. M., Frau, F., Mook-Kanamori, D., Staiger, H., Thomas, E. L., ... Yaghootkar, H. (2019).
Genome-Wide and Abdominal MRI-Imaging Data Provides Evidence that a Genetically Determined Favourable
Adiposity Phenotype is Characterized by Lower Ectopic Liver Fat and Lower Risk of Type 2 Diabetes, Heart
Disease and Hypertension. Diabetes, 68(1), 207-219. https://doi.org/10.2337/db18-0708
 Genome-wide and abdominal MRI-imaging data provides evidence that a 
genetically determined favourable adiposity phenotype is characterized by lower 
ectopic liver fat and lower risk of type 2 diabetes, heart disease and 
hypertension. 
Yingjie Ji*1, Andrianos M. Yiorkas*2,3, Francesca Frau*4, Dennis Mook-
Kanamori*5,6, Harald Staiger*7,8,9, E. Louise Thomas10, Naeimeh Atabaki-Pasdar11, 
Archie Campbell12, Jessica Tyrrell1, Samuel E. Jones1, Robin N. Beaumont1, Andrew 
R. Wood1, Marcus A. Tuke1, Katherine S. Ruth1, Anubha Mahajan13, Anna Murray1, 
Rachel M. Freathy1, Michael N. Weedon1, Andrew T. Hattersley14, Caroline 
Hayward15, Jürgen Machann7,8, Hans-Ulrich Häring7,8,16, Paul Franks11,17,18, Renée de 
Mutsert5, Ewan Pearson19, Norbert Stefan*7,8,16, Timothy M. Frayling*1, Karla V. 
Allebrandt*4, Jimmy D. Bell*10, Alexandra I. Blakemore*2,3, Hanieh Yaghootkar*#1 
* Contributed equally
# Corresponding author
1- Genetics of Complex Traits, University of Exeter Medical School, University of 
Exeter, RILD Level 3, Royal Devon & Exeter Hospital, Barrack Road, Exeter EX2 
5DW, UK 
2- Section of Investigative Medicine, Imperial College London, London W12 0NN, 
UK 
3- Department of Life Sciences, Brunel University London, Uxbridge UB8 3PH, UK 
4- Translational Medicine and Early Development, TMED Translational Informatics, 
Sanofi, Frankfurt am Main, Germany 
5- Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, 
the Netherlands 
6- Department of Public Health and Primary Care, Leiden University Medical Center, 
Leiden, the Netherlands 
7- Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center 
Munich at the University of Tübingen, Otfried Müller Strasse 10, 72076 Tübingen, 
Germany 
8- German Center for Diabetes Research (DZD), Otfried-Müller-Strasse 10, 72076 
Tübingen, Germany 
9- Institute of Pharmaceutical Sciences, Department of Pharmacy and Biochemistry, 
Eberhard Karls University Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, 
Germany 
10- Research Centre for Optimal Health, School of Life Sciences, University of 
Page 2 of 96
Diabetes
 
Diabetes Publish Ahead of Print, published online October 23, 2018
This is an author-created, uncopyedited electronic version of an article accepted for publication in Diabetes. The American Diabetes Association (ADA), 
publisher of Diabetes, is not responsible for any errors or omissions in this version of the manuscript or any version derived from it by third parties. The definitive 
publisher-authenticated version will be available in a future issue of Diabetes in print and online at http://diabetes.diabetesjournals.org/content/early/2018/10/16/
db18-0708.article-info
 Westminster, London, UK 
11- Department of Clinical Sciences, Genetic and Molecular Epidemiology Unit, 
Lund University, Skåne University Hospital Malmö, SE-21741, Malmö, Sweden. 
12- Generation Scotland, Centre for Genomic and Experimental Medicine, Institute of 
Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK 
13- Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK. 
14- Institute of Biomedical and Clinical Science, University of Exeter Medical 
School, Exeter EX2 5DW, UK 
15- Medical Research Council Human Genetics Unit, Institute of Genetics and 
Molecular Medicine, University of Edinburgh, Edinburgh, UK 
16- Department of Internal Medicine IV, Division of Endocrinology, Diabetology, 
Angiology, Nephrology and Clinical Chemistry, Eberhard Karls University Tübingen, 
Otfried-Müller-Strase 10, 72076 Tübingen, Germany 
17- Department of Public Health & Clinical Medicine, Umeå University, Umeå, 
Sweden. 
18- Department of Nutrition, Harvard School of Public Health, Boston, MA, USA. 
19- Division of Molecular and Clinical Medicine, University of Dundee, Ninewells 
Hospital, Dundee, UK 
Corresponding author: Hanieh Yaghootkar 
University of Exeter Medical School, RILD building Level 3, Royal Devon & Exeter 
Hospital, Barrack Road, Exeter, EX2 5DW 
E-mail: h.yaghootkar@exeter.ac.uk 
Work count: 4,200 
Number of tables and figures: 5 
Page 3 of 96
Diabetes
 Abstract (200 words) 
Recent genetic studies have identified alleles associated with opposite effects on 
adiposity and risk of type 2 diabetes. We aimed to identify more of these variants and 
test the hypothesis that such “favourable adiposity” alleles are associated with higher 
subcutaneous fat and lower ectopic fat. We combined magnetic resonance imaging 
(MRI) data with genome-wide association studies (GWAS) of body fat % and 
metabolic traits. We report 14 alleles, including 7 newly characterized alleles, 
associated with higher adiposity, but a favourable metabolic profile. Consistent with 
previous studies, individuals carrying more “favourable adiposity” alleles had higher 
body fat % and higher BMI, but lower risk of type 2 diabetes, heart disease and 
hypertension. These individuals also had higher subcutaneous fat, but lower liver fat 
and lower visceral-to-subcutaneous adipose tissue ratio. Individual alleles associated 
with higher body fat % but lower liver fat and lower risk of type 2 diabetes included 
those in PPARG, GRB14 and IRS1, whilst the allele in ANKRD55 was paradoxically 
associated with higher visceral fat but lower risk of type 2 diabetes. Most identified 
“favourable adiposity” alleles are associated with higher subcutaneous and lower liver 
fat, a mechanism consistent with the beneficial effects of storing excess triglyceride in 
metabolically low risk depots.   
 
Page 5 of 96
Diabetes
 Introduction 
There are many overweight or obese individuals who do not carry the expected 
metabolic disease risks associated with higher BMI (1; 2) while some lean or normal 
weight individuals develop diseases like type 2 diabetes(3-5). We(6; 7) and others(8-
10) have previously shown that genetic variation is likely to contribute to these 
differences by increasing adiposity but lowering the risk of type 2 diabetes. We 
labelled these variants “favourable adiposity” since the alleles associated with higher 
BMI are associated with a favourable metabolic profile and lower risk of type 2 
diabetes. The alternative alleles of the same variants could be characterized as 
“unfavorable lack of adiposity” or “limited adipose tissue storage capacity”. The 
identification of these variants differed by study. One study started with a genome-
wide association study (GWAS) of body fat % in 76,150 individuals and showed that 
a common allele near the IRS1 gene was associated with higher adiposity but lower 
insulin resistance and risk of disease(8). The remaining studies were limited to genetic 
variants associated with fasting insulin levels at genome-wide levels of statistical 
confidence and used a combination of data and approaches to identify genetic scores 
of between 10 and 53 variants that collectively were associated with opposite effects 
on BMI and risk of type 2 diabetes(6; 7; 9; 10).  
More detailed characterization of these alleles revealed several insights. First, the 
alleles associated with higher BMI but lower risk of type 2 diabetes were associated 
with a lower risk of hypertension and heart disease as well as type 2 diabetes(6; 7; 9). 
Second, most of the alleles associated with higher insulin sensitivity, as identified by 
GWAS of fasting insulin levels, were associated with higher BMI or a redistribution 
of fat into the lower body, as estimated by waist-to-hip ratio(6; 7; 9; 10). Third, these 
Page 6 of 96
Diabetes
 alleles were associated with more refined measures of adipose tissue distribution: the 
alleles associated with higher BMI but lower risk of disease were also associated with 
higher adiposity in the lower body (gynoid area and legs) as measured by DEXA(9).  
The association of “favourable adiposity” alleles with higher peripheral adiposity in 
the previous studies proposed that a likely explanation for the mechanism is altered 
adipose tissue storage capacity(6; 7; 9; 10) consistent with the “adipose tissue 
expandability” hypothesis(11). To have a clear understanding about the underlying 
mechanisms associated with “favourable adiposity” in the context of the “adipose 
tissue expandability” hypothesis, we need to study whether “favourable adiposity” 
alleles are specifically associated with lower levels of ectopic fat. Furthermore, since 
men and women have different body fat distribution regulated by sex steroids(12), the 
study of underlying mechanisms separately in men and women may help elucidate the 
biology of the cardio-metabolic diseases. 
The aim of this study was to identify additional alleles associated with “favourable 
adiposity” and to combine genetic and MRI data to understand more about the 
underlying mechanisms. In contrast to most previous studies, that focused on variants 
associated with surrogate measures of insulin resistance (fasting insulin), we started 
with variants associated with altered body fat %. We describe an approach that led to 
the characterization of 14 alleles collectively associated with higher body fat % but 
lower risk of type 2 diabetes, hypertension and heart disease. We showed that these 
alleles are associated with lower ectopic fat in the liver, based on MRI data.  
 
 
 
Page 7 of 96
Diabetes
 Method 
UK Biobank study: UK Biobank recruited over 500,000 individuals aged 37-73 
years (99.5% were between 40 and 69 years) between 2006-2010 from across the UK 
(supplementary table 1). The study has been described in more detail elsewhere(13).  
UK Biobank genetic data: SNP genotypes underwent extensive central quality 
control (http://biobank.ctsu.ox.ac.uk). We based our study on 451,099 individuals of 
white European descent as defined by Principal Components Analysis (PCA). Briefly, 
principal components were generated in the 1000 Genomes Cohort using high-
confidence SNPs to obtain their individual loadings. These loadings were then used to 
project all of the UK Biobank samples into the same principal component space and 
individuals were clustered using principal components 1-4. We removed 7 
participants who withdrew from the study, and 348 individuals whose self-reported 
sex did not match their genetic sex based on relative intensities of X and Y 
chromosome SNP probe intensity. 
Measures of disease and disease related traits in UK Biobank: We used 3 cardio-
metabolic diseases: type 2 diabetes, hypertension (also represented by continuous 
measures of systolic and diastolic blood pressure) and heart disease – all using 
baseline data and following similar definitions to those used in previous GWASs 
(supplementary table 1). 
We defined type 2 diabetes cases using baseline data if 3 criteria were present: i) 
reports of diabetes at the interview, ii) at least one year gap from diagnosis without 
requiring insulin, iii) reported age at diagnosis over the age of 35 years to limit the 
numbers of individuals with slow-progressing autoimmune diabetes or monogenic 
forms. Individuals not reporting an age of diagnosis were excluded. We also excluded 
Page 8 of 96
Diabetes
 individuals diagnosed with diabetes within the year prior to the baseline study visit as 
we were unable to determine whether they were using insulin within the first year. 
Controls were individuals not fulfilling these criteria. 
We defined subjects as hypertensive if systolic blood pressure was >140 mmHg, or a 
diastolic blood pressure was >90 mmHg, or blood pressure medication was reported. 
Controls were individuals not fulfilling these criteria. For the analysis of systolic and 
diastolic blood pressure, we corrected blood pressure measures in people on 
antihypertensive drugs by adding 15 mmHg to systolic and 10 mmHg to diastolic 
blood pressure.  
We defined heart disease cases if individuals reported angina and/or a heart attack at 
the interview stage. We defined controls as individuals without these conditions.  
Identification of genetic variants associated with “favorable adiposity” 
We designed a study in three steps to identify genetic variants associated with 
“favourable adiposity” (supplementary figure 1).  
First, genetic variants associated with adiposity. We used Bio-impedance measures 
of body fat % measured by the Tanita BC418MA body composition analyser as 
measure of adiposity (N = 442,278 individuals from UK Biobank). We used a linear 
mixed model implemented in BOLT-LMM to account for population structure and 
relatedness(14). We used age, sex, genotyping platform, study centre and the first 5 
principal components as covariates in the model.  
Second, genetic variants associated with a multivariate metabolic outcome: We 
used summary statistics from published GWASs (not including UKBiobank) of 
metabolic biomarkers including body fat % (N = 120,000)(15), HDL-C (99,900)(16), 
Page 9 of 96
Diabetes
 adiponectin (29,400)(17), sex hormone binding globulin (SHBG, 21,800)(18), 
triglycerides (96,600)(16), fasting insulin (51,800)(19), and alanine transaminase 
(55,500)(20). We used these biomarkers to be consistent with our previous 
approach(7). These biomarkers are used to discriminate monogenic disorders of fat 
storage (lipodystrophy) from other monogenic conditions where insulin sensitivity 
and adiposity are affected(7; 21; 22).  
Within each GWAS, we standardized the effect sizes to correct for the differences in 
sample size and the various traits measurement unit across different GWAS: 
���������������� =
����
�� ∗ √� 
We used metaCCA(23) to run a multivariate GWAS. The phenotype-phenotype 
correlation matrix (ΣˆYY=cov(Y, Y)) was built according to the Pearson correlation 
between any pairs of traits across genome-wide genetic variants. Genotype-genotype 
correlation matrix (ΣˆXX=cov(X, X)) was computed using reference database from 
1000 Genomes. The canonical correlation analysis in metaCCA finds the maximal 
correlation coefficient R_metaCCA between genetic variants and linear combination 
of phenotypes based on phenotype-phenotype correlation matrix. We defined genetic 
variants associated with a multivariate metabolic outcome if metaCCA p < 5x10-8. 
Third, genetic variants associated with “favourable adiposity”. We selected 
genetic variants associated with both adiposity (step 1) and a multivariate metabolic 
outcome (step 2) at p < 5x10-8 and used a hierarchical clustering approach to narrow 
down the list to ones showing a pattern of “favourable adiposity”. We calculated the 
frequency of times the variants were in the same cluster to identify “favourable 
adiposity” cluster using the “pvclust” package in R as shown before(7). 
Page 10 of 96
Diabetes
 Genetic score analysis 
We constructed the genetic score of “favorable adiposity” variants as the number of 
“favorable adiposity” alleles carried by each individual (un-weighted). We used age, 
sex, genotyping platform, study center and the first 5 ancestry principal components 
as covariates in the model.  
Additional studies for replication of the non-imaging findings  
To provide further evidence for the role of “favorable adiposity” alleles, we used 5 
cohorts that were not part of the published GWASs used in our discovery stage 
(supplementary table 1): NEO study (The Netherlands Epidemiology of Obesity; 
6,671 individuals of white European descent collected from the greater area of Leiden 
in the West of the Netherlands(24)), EXTEND (Exeter 10,000; 7,340 individuals of 
white European descent collected from South West England), GS:SFHS (Generation 
Scotland: Scottish Family Health Study; 20,000 individuals of white European 
descent collected from Scotland(25)), TÜF (Tübingen Family Study for Type 2 
Diabetes; 2,679 individuals of white European descent collected from Southern 
Germany(26)), and IMI-DIRECT (Diabetes Research on Patient Stratification; 3,029 
Caucasian pre-diabetic and Type 2 Diabetes subjects recruited by clinical centers 
located across Europe(27)).  
To further provide evidence for the role of “favorable adiposity” alleles in risk of 
cardiometabolic diseases, we used published GWAS studies of type 2 diabetes(28), 
heart disease(29) and blood pressure(30). 
Studies contributed to imaging findings (liver fat, visceral fat and subcutaneous 
fat): 
Page 11 of 96
Diabetes
 UK Biobank: We used 5,045 individuals who had available data obtained through 
UK Biobank Access Application number 9914 and 6569. Participants were MRI 
scanned as previously described(31). Briefly, a single transverse slice located at the 
liver was acquired from each subject using multi-echo spoiled-gradient-echo 
acquisition and analysed as previously described(32). Assessment of abdominal 
subcutaneous and visceral fat was described previously(33).   
NEO: Abdominal subcutaneous and visceral fat was assessed in 2,236 participants 
using MRI and were quantified by a turbo spin echo imaging protocol. At the level of 
the 5th lumbar vertebra 3 transverse images each with a slice thickness of 10 mm 
were obtained during a breath-hold. Proton (1H)-MRS of the liver was used to assess 
hepatic triglyceride content (N = 1,821)(24). 
TÜF: The TÜF study contributed subcutaneous and visceral adipose tissue 
measurements from 833 and 906 genotyped individuals, respectively, who underwent 
whole body magnetic resonance tomography. The two fat depots were quantified by 
an axial T1-weighed fast spin echo technique with a 1.5 T whole-body imager 
(Magnetom Sonata, Siemens Healthcare), as previously described(26). Liver fat 
measurements were available from 911 genotyped individuals who underwent 
localized 1H magnetic resonance spectroscopy, as described(26).  
IMI-DIRECT: The IMI-DIRECT consortium is a collaboration among investigators 
from a range of European academic institutions and pharmaceutical companies. Liver 
fat was assessed on 1,457 subjects using a multi-echo acquisition as previously 
described(34). Briefly, the liver was identified from a scout abdominal image and 
axial images were performed during suspended respiration, which were used to 
position a single slice multi-echo sequence through the liver.  
Page 12 of 96
Diabetes
 Published GWAS: We used published genome-wide association study of 
subcutaneous and visceral fat distribution as measured by CT scan or MRI(35). 
Page 13 of 96
Diabetes
 Results 
We identified 14 alleles associated with “favourable adiposity”  
Using a 3-step approach, we characterized 14 genetic variants associated with 
“favourable adiposity”. Of these variants, seven were previously known to be 
associated with a “favourable adiposity” phenotype - those in/near PPARG, 
LYPLAL1, GRB14, IRS1, PEPD, FAM13A and ANKRD55, five were known to be 
associated with a relevant trait, but not confirmed as having a “favourable adiposity” 
phenotype, (those in/near TRIB1, KLF14/MKLN1, DNAH10, VEGFA/C6orf223 and 
AEBP2/PDE3A) and two were entirely novel (those in/near MAFF and CITED2) 
(supplementary table 2). Twelve of the 14 variants had not previously been 
associated with body fat % at genome-wide levels of statistical confidence.   
In the first step (supplementary figure 1), we performed a GWAS of body fat % in 
442,278 individuals in the UK Biobank. We identified 620 variants at p<5x10-8. In the 
second step, we used published GWAS statistics from 7 circulating biomarkers of 
metabolic health and identified 33 of these 620 variants as associated with a 
multivariable metabolic phenotype. This approach identifies alleles associated with 
metabolic traits after accounting for the phenotypic correlation between higher 
adiposity and these metabolic traits (supplementary table 3 & 4, supplementary 
figure 2). For example, this approach has more power to detect alleles paradoxically 
associated with higher adiposity but a favourable metabolic profile, because the 
model accounts for the population level correlation between higher adiposity and an 
adverse metabolic profile. The resulting 33 alleles also included some alleles 
associated very strongly with higher BMI and adverse metabolic profile, such as the 
allele in the FTO gene, most likely because adjusting for body fat % in the model 
Page 14 of 96
Diabetes
 does not fully account for the adverse metabolic effects of lifelong higher adiposity. 
We therefore undertook a third step where we further refined the phenotypic 
characteristics of these variants by performing a clustering analysis. This approach led 
to the clustering of 14 alleles associated with “favourable adiposity” as defined by 
association with higher body fat %, HDL-C, SHBG and adiponectin levels, and lower 
triglycerides, alanine transaminase and fasting insulin levels (supplementary figure 
3). We validated the effect of the 14 “favourable adiposity” alleles together in a 
genetic score on levels of metabolic biomarkers using 5 independent studies: NEO, 
EXTEND, GenScotland, TÜF and IMI-DIRECT (supplementary table 5). 
A genetic score of “favourable adiposity” alleles was associated with lower risk of 
cardiometabolic disease outcomes. 
Carrying additional "favourable adiposity" alleles was associated with higher body fat 
% and higher BMI but lower risk of type 2 diabetes, hypertension and heart disease 
(table 1). For example, the 10% of people carrying the most “favourable adiposity” 
alleles had approximately 1.04% higher body fat % (95%CI [0.95,1.13], p=6x10-115) 
and 0.4 kg/m2 higher BMI ([0.32,0.45], 3x10-29) but 0.66 OR lower risk of type 2 
diabetes ([0.61,0.72], 7x10-23), 0.87 lower risk of hypertension ([0.84,0.90], 1x10-19) 
and 0.84 OR lower risk of heart disease ([0.80,0.89], 6x10-10) compared to the 10% of 
people carrying the fewest “favourable adiposity” alleles (data from UK Biobank) 
(figure 1). These effects were similar in men and women and when we removed the 
seven known "favourable adiposity" variants from the analysis (table 1). These 
associations were similar when using data from published GWASs (supplementary 
table 6). For each of the 14 individual variants, the body fat % increasing allele was 
associated with at least one of lower risk of type 2 diabetes, lower risk of heart disease 
Page 15 of 96
Diabetes
 or lower diastolic or systolic blood pressure in UK Biobank except the variant at the 
AEBP2 locus (supplementary figure 4). In published GWAS data the exceptions 
were the variants at the AEBP2 and MAFF loci (supplementary table 6).  
Individual “favourable adiposity” alleles were associated with heterogeneous 
effects on waist-to-hip ratio. 
Five of the individual 14 variants were previously identified as associated with waist-
to-hip ratio(36). Previous studies have pointed out that the disease-protective effect of 
these alleles is likely to be due to their association with redistribution of the extra fat 
into the lower body (defined by lower waist-to-hip ratio). We therefore examined the 
alleles’ association with waist-to-hip ratio in more detail. Carrying more “favourable 
adiposity” alleles was associated with lower waist circumference (p=3.7x10-5) but 
higher hip circumference (2.3x10-109) in women. However, in men, carrying more 
“favourable adiposity” alleles was associated with higher waist circumference 
(1.7x10-40), higher hip circumference (1.8x10-53) and no effect on waist-to-hip ratio 
(supplementary table 7). These associations were robust when limiting the variants 
to the 7 not previously identified as having a “favourable adiposity” phenotype 
(supplementary table 7). The individual variants were associated with heterogeneous 
effects on waist-to-hip ratio. Most notably, for two variants, those in/near PPARG and 
ANKRD55, the “favourable adiposity” allele was not associated with lower waist-to-
hip ratio in women, and for ANKRD55, it was associated with higher waist-to-hip 
ratio (figure 2). 
“Favourable adiposity” alleles were associated with less liver fat and more 
abdominal subcutaneous fat. 
Page 16 of 96
Diabetes
 We next investigated the associations between the “favourable adiposity” variants and 
MRI measures of subcutaneous, visceral and liver fat using data from 9,434  
individuals and 4 studies – the first wave of UK Biobank imaging data (n=5,045), 
NEO (2,236), IMI-DIRECT (1,323) and TÜF (906). A fifth set of data did not include 
liver fat and came from a published meta-analysis of 13 studies with abdominal MRI 
or CT scans of 18,332 individuals(35).  
The genetic score of “favourable adiposity” alleles was associated with lower 
visceral-to-subcutaneous adipose tissue ratio p=2x10-14) in both men and women. 
This effect was driven by association with more subcutaneous fat (p=2x10-14; table 2, 
figure 3). All 14 individual genetic variants were associated with higher subcutaneous 
adipose tissue, seven at p<0.05 (in/near DNAH10, FAM13A, GRB14, KLF14, 
LYPLAL1, IRS1 and PPARG). Nine individual “favourable adiposity” alleles were 
associated with lower visceral-to-subcutaneous adipose tissue volume ratio, all at p < 
0.05 (in/near CITED2, DNAH10, FAM13A, KLF14, LYPLAL1, IRS1, PPARG, TRIB1 
and VEGFA; supplementary figure 4, supplementary table 8). Paradoxically, the 
“favourable adiposity” alleles in/near ANKRD55 and PEPD were associated with 
higher visceral-to-subcutaneous adipose tissue volume ratio (p=0.001 and 0.02, 
respectively). 
The genetic score of “favourable adiposity” was associated with lower liver fat in 
women (p=6.3x10-9) but was not associated with liver fat in men (p=0.8; table 2, 
figure 3). These effects were robust when limiting the variants to the 7 not previously 
identified as having a “favourable adiposity” phenotype (table 2). For 11 individual 
variants, the allele associated with higher subcutaneous fat was associated with lower 
Page 17 of 96
Diabetes
 liver fat, four with p<0.05 (in/near CITED2, GRB14, PPARG and TRIB1 
(supplementary figure 4, supplementary table 8).  
Sensitivity analysis of liver fat.  
We performed three sensitivity analyses to assess whether the effect of “favourable 
adiposity” alleles on lower liver fat was affected by menopause, inclusion of type 2 
diabetes patients or alcohol consumption.  
First, menopause leads to a redistribution of adipose tissue towards more central 
obesity and an android phenotype(37; 38). To study whether or not the association 
with liver fat in women was influenced by menopausal status, we divided women 
from the UK Biobank and TÜF studies into pre- and post-menopausal status. The 
association between “favourable adiposity” alleles and lower liver fat in pre-
menopausal women was twice that (-0.258 % [-0.223,-0.293]; p=0.002; n=433) of 
post-menopausal women (-0.124 % [-0.106,-0.142]; p=0.002; n=2,356) but the 
difference was not statistically meaningful (Pdifference=0.14; supplementary table 9). 
Second, fatty liver disease is very common (>50%) in patients with type 2 
diabetes(39). To check whether inclusion of people with type 2 diabetes had affected 
the association with liver fat, we ran the tests in UK Biobank individuals excluding 
people diagnosed with type 2 diabetes (n=222) from the analysis of liver fat. The 
association of “favourable adiposity” alleles with liver fat remained similar after 
exclusion of patients with type 2 diabetes in all, men and women (all Pdifference>0.7; 
supplementary table 10). 
Third, the most common cause of increased fat in the liver is alcohol consumption 
which is more prevalent in men(40; 41). To study whether or not the lack of 
Page 18 of 96
Diabetes
 association with liver fat in men was due to greater alcohol consumption, we assessed 
the effect of “favourable adiposity” alleles on liver fat in men defined as heavy, 
moderate and non-drinkers based on self-report alcohol questionnaires. The 
“favourable adiposity” alleles were not associated with liver fat in any of the three 
groups (supplementary table 11). 
 
Page 19 of 96
Diabetes
 Discussion 
We characterized 14 genetic variants associated with “favourable adiposity”. Our 
study adds to previous studies(6; 7; 9; 10) in several ways. First, we outlined a new 
approach which leads to the identification of more “favourable adiposity” variants. 
Second, we provide more clarity about which individual alleles are likely “favourable 
adiposity” alleles and how they affect metabolic traits and diseases. Third, we used 
MRI data which strongly suggests these variants have a collective effect on lower 
liver fat as well as higher subcutaneous fat but they have little detectable effect on 
visceral fat. Finally, we provide a template for detecting alleles with apparently 
paradoxical effects on adiposity and disease using a wide variety of publically 
accessible GWAS data. In addition, our results strengthen previous observations 
including the “favourable adiposity” effect is not driven by altered body shape in men 
detectable by waist-to-hip ratio (6). 
Of the 14 variants detected, 12 had been associated with at least one metabolic trait, 
including fasting insulin (those in/near LYPLAL1, GRB14, IRS1, FAM13A, ANKRD55 
and PEPD (42)), lipid levels (those in/near GRB14, IRS1, KLF14, TRIB1 and 
DNAH10 (16)), adiponectin (those in/near TRIB1, DNAH10 and AEBP2(17)) and 
alanine transaminase (TRIB1(20)). However, only two were known to be associated 
with body fat % (those in/near GRB14 and IRS1(15)) at genome-wide levels of 
statistical confidence. Our data provides several insights about individual variants. 
First, the alleles at PPARG, GRB14 and IRS1 are associated with higher body fat % 
but lower liver fat and lower risk of type 2 diabetes. Second, the allele in ANKRD55 is 
paradoxically associated with higher visceral fat but lower risk of type 2 diabetes. In 
agreement with this finding, this variant is in high linkage disequilibrium (R2= 0.97) 
Page 20 of 96
Diabetes
 with another variant (rs459193) found to associate with lower waist circumference, 
but higher 2-houre glucose levels(43). Third, the allele in TRIB1 is associated with 
higher body fat %, lower visceral fat, lower liver fat and lower risk of heart disease 
and hypertension but it does not have any detectable effect on type 2 diabetes. Fourth, 
4 variants we previously noted as favourable adiposity were not detected in this study. 
These variants (in or near PDGFC, PEPD, RSPO3 and TET2) may alter body fat 
distribution or other aspects of body composition without altering overall body fat %, 
and hence were not detected at p<5x10-8 in stage 1. 
A key question is whether or not the “favourable adiposity” effect is entirely due to 
preferential storage of the excess adiposity in the lower body as proposed before(36; 
44). We made two general observations. First, despite similar effects on higher body 
fat % and lower risk of disease in each sex, the protective effect in men was not 
characterized by preferentially more fat in the lower body, as estimated by waist-to-
hip ratio, consistent with our previous observation(6). Second, the individual variants 
were associated with heterogeneous effects on waist-to-hip ratio even within women. 
For example the allele in/near ANKRD55 was associated with “favourable adiposity” 
but higher waist-to-hip ratio in women. 
Having established that the “favourable adiposity” effect is not driven by preferential 
storage of fat in the lower body, as estimated by waist-to-hip ratio, in men, we 
examined more detailed measures of fat redistribution using MRI data. The 
association with lower liver fat was only detected in women. Our sensitivity analyses 
did not find hormonal differences due to menopause, alcohol consumption or type 2 
diabetes as possible explanations for sex differences. We would expect the 
“favourable adiposity” alleles to be associated with liver fat in non-drinkers or 
Page 21 of 96
Diabetes
 moderate drinkers if the alcohol intake in men confounded the association. However, 
the analysis stratified by alcohol intake in men did not show any association. The lack 
of association with visceral fat suggests that these alleles were not protecting from 
disease due to lower visceral fat. This observation is consistent with some studies 
which showed lower ectopic fat accumulation in the liver may be more important than 
visceral fat in protection from risk of type 2 diabetes(45). A caveat to this conclusion 
is that we used a marker of liver fat, alanine transaminase, as one of the metabolic 
biomarkers to identify the variants, and therefore will be biased towards those that 
affect liver more than visceral fat. 
Our approach provides a framework for identifying additional alleles with apparently 
paradoxical effects on adiposity and disease. A previous study(9) used a simple and 
effective approach by taking published GWAS data and selecting all variants 
associated with higher fasting insulin adjusted for BMI, lower HDL-C and higher 
triglycerides  at p<0.005 for each of the three traits. However, this approach has 
limitations for two reasons, first it applies an arbitrary cut-off for the three traits, and 
second, it does not use information from other biomarkers. We combined GWASs of 
seven metabolic biomarkers and used a multivariate test that does not require 
individual trait associations to reach a certain statistical threshold. We showed that 
our method performs well, as it was able to identify the 7 variants previously known 
to be associated with “favourable adiposity” as well as 7 additional variants that we 
then validated in independent GWAS data. Furthermore, by including SHBG, 
adiponectin and ALT in the model, we had more power to detect “favourable 
adiposity” variants (supplementary table 12). 
Page 22 of 96
Diabetes
 The identification of “favourable adiposity” alleles highlights genes that may be 
targets for novel insulin-sensitizing agents. The allele in PPARG provides an 
important proof of principle because thiazolidinediones are PPAR-γ agonists and 
appear to lower glucose levels despite increasing the patient’s weight by activating 
adipocyte differentiation, which redistributes fat away from liver towards an 
expanded subcutaneous depot(46; 47). The variants identified in our study do not 
identify which genes they are acting through; however, previous studies suggest some 
strong candidates. For example, TRIB1 encodes a protein critical for adipose tissue 
maintenance and suppression of metabolic disorders(48). Mice lacking Trib1 show 
diminished adipose tissue mass and increased lipolysis even when on a normal 
diet(48). GWAS studies in humans have implicated TRIB1 in lipid metabolism(16) 
and regulation of hepatic lipogenesis(20). Higher levels of VEGF-A in mice can 
facilitate healthy expansion of adipose tissue and protect from lipotoxicity and 
metabolic disease(49). CITED2 is required for optimal PPARγ activation(50). 
FAM13A encodes a protein enriched in mature adipocytes and plays an important role 
in the insulin signaling cascade(51) by protecting IRS1 (insulin receptor substrate 1) 
from degradation(51). The proteins encoded by IRS1 and CCDC92 are associated 
with adipogenesis, lipid accumulation and adipocyte differentiation ability(9; 51). 
Functional studies suggest DNAH10 is involved in adipocyte differentiation 
capacity(9). KLF14 is a master regulator of gene expression in adipose tissue(52) 
associated with adipocyte cell size in humans(53). MAP3K1 regulates expression of 
IRS1(54). LYPLAL1, as a triglyceride lipase, is over-expressed in subcutaneous 
adipocytes of obese people to maintain triglycerides metabolism(55). The regulation 
of Grb14 expression in adipose tissue may play a physiological role in insulin 
sensitivity(56). AEBP2 regulates a gene encoding a fatty acid-binding protein. 
Page 23 of 96
Diabetes
 Our study had a number of limitations. First, we used 7 metabolic biomarkers from 
published GWASs in our multivariate analysis. The sample size for each GWAS was 
different: ranging from 21,800 individuals from GWAS of SHBG to 99,900 from the 
GWAS of lipids. These differences, caused by using GWAS meta-analysis data from 
different studies, will have limited our power, and led to less accurate estimates of the 
correlation between phenotypes compared to having the same sample size for all 
phenotypes. Second, the published GWASs of biomarkers were performed in men and 
women together rather than in a sex specific way. As men and women have different 
body fat distribution, it seems necessary to perform the discovery of “favourable 
adiposity” variants in men and women separately when data becomes available. 
Third, we used bio-impedance measures of body fat % as measure of adiposity in the 
discovery step. This measure of adiposity is an imprecise measure and is not as 
accurate in calculating body fat % in obese individuals or people with higher muscle 
mass(57). However, it’s availability in 442,278 individuals meant it represented a 
powerful dataset from which to start(58). Fourth, individual variants had subtle effect 
sizes; all variants were associated with at least one disease, with the body fat % 
increasing allele associated with lower risk except the one at AEBP2 locus; although 
this variant had a paradoxical effect on adiposity and metabolic biomarkers with 
significant association between body fat % increasing allele and higher adiponectin 
(p= 4.76x10-8), higher HDL-C (p=2.83x10-6) and lower triglycerides (p=0.003; 
supplementary table 4). 
To yield a better understanding of how “favourable adiposity” protects against 
cardiometabolic disease, more studies in future are warranted. First, it will be 
important to test the association of “favourable adiposity” variants with pancreatic fat 
as a potential cause of β-cell dysfunction that will inform the associations with type 2 
Page 24 of 96
Diabetes
 diabetes. Second, there are substantial ethnic differences in diabetes risk by BMI with 
South Asians having a much higher risk of type 2 diabetes for a given BMI compared 
to Europeans(59). Study of the genetics of “favourable adiposity” in different ethnic 
groups may provide important insights into the mechanisms underpinning the 
significant ethnic differences in diabetes risk. 
In summary, our study provides further genetic evidence that the balance of 
subcutaneous to ectopic liver fat is an important factor for type 2 diabetes, heart 
disease and hypertension. This finding is consistent with data from monogenic forms 
of lipodystrophy and the importance of an expandable subcutaneous adipose tissue as 
a protective disease mechanism and limited adipose storage capacity as a risk 
mechanism (based on the opposite alleles) as proposed in previous studies(60-62). 
 
 
Page 25 of 96
Diabetes
 Acknowledgment 
The authors thank University of Exeter Medical School. EXTEND data were 
provided by the Peninsula Research Bank, part of the NIHR Exeter Clinical Research 
Facility. This work has been supported by EFSD/Novo Nordisk. The research was 
supported by the National Institute for Health Research (NIHR) Exeter Clinical 
Research Facility. We gratefully acknowledge Dr. Harald Grallert and Dr. Jennifer 
Kriebel (both Helmholtz Center Munich) for genotyping the TÜF samples. This 
research has been conducted using the UK Biobank resource. This work was carried 
out under UK Biobank project numbers 9072, 9055 and 9914. Details of patient and 
public 
involvement 
in 
the 
UK 
Biobank 
are 
available 
online 
(http://www.ukbiobank.ac.uk/about-biobank-uk/ 
and 
https://www.ukbiobank.ac.uk/wp-content/uploads/2011/07/Summary-EGF-
consultation.pdf?phpMyAdmin=trmKQlYdjjnQIgJ%2CfAzikMhEnx6). No patients 
were specifically involved in setting the research question or the outcome measures, 
nor were they involved in developing plans for recruitment, design, or implementation 
of this study. No patients were asked to advise on interpretation or writing up of 
results. There are no specific plans to disseminate the results of the research to study 
participants, but the UK Biobank disseminates key findings from projects on its 
website. The authors of the NEO study thank all individuals who participated in the 
Netherlands Epidemiology in Obesity study, all participating general practitioners for 
inviting eligible participants and all research nurses for collection of the data. We 
thank the NEO study group, Pat van Beelen, Petra Noordijk and Ingeborg de Jonge 
for the coordination, lab and data management of the NEO study. The genotyping in 
the NEO study was supported by the Centre National de Génotypage (Paris, France), 
headed by Jean-Francois Deleuze. 
Page 26 of 96
Diabetes
 Author Contributions: Designed, led the study and wrote the manuscript: HY. 
Quality-controlled the data in UK Biobank: JT, SEJ, RNB, ARW, MAT, KSR, AM, 
RMF, MNW, HY, TMF. Performed statistical analysis/provided data in UK Biobank 
(YJ, HY, AMY, JDB, AIB), NEO (DOM-K, RDM), IMI-DIRECT (FF, ELT, NAP, 
AM, PF, KVA, EP, JDB), TUF (HS, JM, HUH, NS), GenScotland (YJ, AC, CH), 
EXTEND (YJ, ATH). All co-authors commented on the manuscript and agreed with 
the manuscript results and conclusions. 
Conflict of interest statement: The authors of this manuscript have the following 
competing interests: SANOFI employees: Francesca Frau and Karla V. Allebrandt. 
Other authors have no conflict of interest. 
Guarantor Statement: HY is the guarantor of this work and, as such, had full access to 
all the data in the study and takes responsibility for the integrity of the data and the 
accuracy of the data analysis. 
Funding: 
HY is funded by Diabetes UK RD Lawrence fellowship (grant: 17/0005594). ARW 
and 
TMF 
are 
supported 
by 
the 
European 
Research 
Council 
(grant 
323195:GLUCOSEGENES-FP7-IDEAS-ERC). RNB and RMF are funded by the 
Wellcome Trust and Royal Society grant 104150/Z/14/Z. JT is funded by the 
European Regional Development Fund (ERDF) and a Diabetes Research and 
Wellness Foundation fellowship. SEJ is funded by the Medical Research Council 
(grant MR/M005070/1). The TÜF study was supported in part by a grant (01GI0925) 
from the German Federal Ministry of Education and Research (BMBF) to the German 
Center for Diabetes Research (DZD) and by a grant from the German Research 
Foundation (DFG KFO114). IMI-DIRECT was supported by the Innovative 
Page 27 of 96
Diabetes
 Medicines Initiative Joint Undertaking under grant agreement n°115317 (DIRECT), 
resources of which are composed of financial contribution from the European Union's 
Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind 
contribution. The NEO study is supported by the participating Departments, the 
Division and the Board of Directors of the Leiden University Medical Center, and by 
the Leiden University, Research Profile Area Vascular and Regenerative Medicine. 
Dennis Mook-Kanamori is supported by Dutch Science Organization (ZonMW-VENI 
Grant 916.14.023). Generation Scotland received core support from the Chief 
Scientist Office of the Scottish Government Health Directorates [CZD/16/6] and the 
Scottish Funding Council [HR03006]. Genotyping of the GS:SFHS samples was 
carried out by the Genetics Core Laboratory at the Wellcome Trust Clinical Research 
Facility, Edinburgh, Scotland and was funded by the Medical Research Council UK 
and the Wellcome Trust (Wellcome Trust Strategic Award “STratifying Resilience 
and Depression Longitudinally” (STRADL) Reference 104036/Z/14/Z). 
The funders had no influence on study design, data collection and analysis, decision 
to publish, or preparation of the manuscript. 
 
Page 28 of 96
Diabetes
 Tables 
 
 
 
 
 
 
 
 
 
 
Page 29 of 96
Diabetes
 Table 1. The effect of “favourable adiposity” genetic score on measures of adiposity and cardiometabolic disease outcome in the UK Biobank 
study. Effects are per carrying additional adiposity allele. 95% CI: 95% confidence interval; P: p-value; N: number; OR: odds ratio. 
 
 
14 SNPs 
7 “additional” SNPs 
 
Trait/disease 
Analysis 
Effect 
95% CI 
P 
Effect 
95% CI 
P 
N  (cases vs. controls) 
Body fat % 
ALL 
0.17 
0.169, 0.171 
6x10-263 
0.15 
0.149, 0.151 
1x10-105 
443,000 
Women 
0.15 
0.148, 0.152 
3.5x10-116 
0.14 
0.138, 0.142 
8.9x10-52 
240,882 
Men 
0.19 
0.188, 0.192 
1x10-165 
0.16 
0.158, 0.162 
3x10-61 
202,118 
BMI (kg/m2) 
ALL 
0.040  
0.039, 0.041 
3.6x10-45 
0.045 
0.044, 0.047 
4.5x10-30 
449,359 
Women 
0.041 
0.039, 0.042 
3x10-28 
0.047 
0.045, 0.049 
1.9x10-19 
243,797 
Men 
0.039 
0.038, 0.041 
1.6x10-22 
0.042 
0.040, 0.045 
6x10-14 
205,528 
Type 2 
diabetes (OR) 
ALL 
0.954  
0.948, 0.960 
4x10-44 
0.966 
0.957, 0.975 
1.9x10-13 
14,371 vs. 428,017 
Women 
0.950 
0.939, 0.961 
3x10-18 
0.962 
0.946, 0.977 
2x10-6 
4,713 vs. 236,073 
Men 
0.960 
0.948, 0.964 
5x10-26 
0.966 
0.955, 0.978 
1x10-8 
9,076 vs. 192,344 
Heart disease  
(OR) 
ALL 
0.984 
0.980, 0.989 
3x10-14 
0.982 
0.976, 0.988 
1.5x10-9 
37,741 vs. 318,892 
Women 
0.987 
0.980, 0.994 
0.0003 
0.981 
0.971, 0.991 
0.0003 
12,270 vs. 184,550 
Men 
0.982 
0.977, 0.987 
2x10-11 
0.983 
0.975, 0.990 
2.6x10-6 
25,363 vs. 134,433 
Hypertension  
(OR) 
ALL 
0.987 
0.985, 0.989 
1x10-33 
0.989 
0.986, 0.992 
3x10-13 
241,691 vs. 206,525 
Women 
0.988 
0.985, 0.991 
2x10-16 
0.989 
0.985, 0.993 
3x10-7 
114,713 vs. 128,623 
Men 
0.985 
0.981, 0.988 
1.7x10-19 
0.987 
0.983, 0.992 
1.6x10-7 
126,978 vs. 77,902 
Systolic blood 
pressure 
(mmHg) 
ALL 
-0.173  
-0.174, -0.172 
9x10-46 
-0.139 
-0.141, -0.138 
3.6x10-16 
450,075 
Women 
-0.163 
-0.165, -0.162 
1x10-22 
-0.134 
-0.136, -0.132 
1x10-8 
244,183 
Men 
-0.206 
-0.208, -0.205 
7.9x10-27 
-0.161 
-0.163, -0.159 
2x10-9 
205,892 
Diastolic 
blood pressure 
(mmHg) 
ALL 
-0.074 
-0.075, -0.073 
7x10-24 
-0.085 
-0.087, -0.083 
1x10-16 
449,322 
Women 
-0.078 
-0.080, -0.077 
1.6x10-14 
-0.093 
-0.095, -0.091 
1x10-10 
243,732 
Men 
-0.073 
-0.074, -0.071 
1.9x10-10 
-0.081 
-0.083, -0.079 
3.5x10-7 
205,590 
Page 30 of 96
Diabetes
  
Table 2. The effect of “favourable adiposity” genetic score on (MRI/CT scan) measures of abdominal adipose tissue using data from 5 studies. 
Effects are per carrying additional adiposity allele. 95% CI: 95% confidence interval; P het: P of heterogeneity test across the 5 studies. 
 
 
14 SNPs 
7 “additional” SNPs 
 
Analysis Beta 
95% CI 
P 
P het 
Beta 
95% CI 
P 
P het 
Subcutaneous 
adipose tissue 
(Litres) 
All 
0.054 
0.042, 0.067 
2x10-14 
0.36 
0.048 
0.029, 0.067 
9.6x10-7 
0.38 
Women 
0.032 
0.016, 0.048 
6x10-5 
0.55 
0.032 
0.010, 0.054 
3x10-3 
0.89 
Men 
0.051 
0.035, 0.067 
2.5x10-11 
0.16 
0.045 
0.022, 0.064 
4.9x10-5 
0.35 
Visceral 
adipose tissue 
(Litres) 
All 
0.005 
-0.007, 0.014 
0.4 
0.69 
-0.002 
-0.016, 0.011 
0.84 
0.94 
Women 
-0.007 
-0.018, 0.005 
0.2 
0.28 
-0.009 
-0.025, 0.005 
0.21 
0.6 
Men 
0.011 
0.000, 0.020 
0.05 
0.05 
0.007 
-0.009, 0.020 
0.43 
0.34 
VATSAT 
ratio 
All 
-0.005 
-0.007, -0.004 
2x10-14 
0.15 
-0.005 
-0.008, -0.004 
4x10-9 
0.75 
Women 
-0.005 
-0.007, -0.003 
1x10-10 
0.46 
-0.006 
-0.008, -0.004 
9x10-8 
0.93 
Men 
-0.004 
-0.005, -0.002 
7x10-7 
0.03 
-0.004 
-0.006, -0.002 
4x10-4 
0.16 
Liver fat (%) 
All 
-0.087 
-0.124, -0.051 
5.6x10-6 
0.015 
-0.060 
-0.115, -0.009 
0.02 
0.015 
Women 
-0.170 
-0.225, -0.110 
6.3x10-9 
0.26 
-0.133 
-0.216, -0.055 
1x10-3 
0.57 
Men 
-0.005 
-0.055, 0.041 
0.8 
0.16 
0.000 
-0.069, 0.069 
0.99 
0.086 
 
Page 31 of 96
Diabetes
 Figures 
Figure 1. Carrying more “favourable adiposity” alleles was associated with higher 
adiposity but lower risk of type 2 diabetes (a), heart disease (b) and hypertension (c). 
We divided individuals from UK Biobank into 10 centiles based on their “favourable 
adiposity” genetic score (x vector). The distribution of “favourable adiposity” genetic 
score is shown in black and the case/control proportion is shown in red per each 
centile. 
Figure 2. The individual variants were associated with heterogeneous effects on 
waist-to-hip ratio. Most notably, for two variants, those in/near PPARG and 
ANKRD55, the “favourable adiposity” allele was not associated with lower waist-to-
hip ratio in women, and for ANKRD55, it was associated with higher waist-to-hip 
ratio. For eleven variants (those in/near IRS1, TRIB1, CITED2, FAM13A, VEGFA, 
AEBP2, KLF14, LYPLAL1, DNAH10, MAFF and GRB14) the “favourable adiposity” 
allele was associated with lower waist-to-hip ratio in women, whilst for the variant 
in/near PEPD there was no clear association with waist-to-hip ratio in either sex. The 
x vector illustrates the effect on body fat % in men (right plot) and women (left plot). 
The y vector illustrates the effect on waist-to-hip ratio. Data is from UK Biobank 
population. 
Figure 3. The effect of “favourable adiposity” genetic score on (MRI/CT scan) 
measures of abdominal adipose tissue using data from 5 studies. The x-axis is the 
effect size per carrying additional “favourable adiposity” allele.  
 
 
Page 32 of 96
Diabetes
 References 
1. Andres R: Effect of obesity on total mortality. Int J Obes 1980;4:381-386 
2. Stefan N, Haring HU, Hu FB, Schulze MB: Metabolically healthy obesity: 
epidemiology, mechanisms, and clinical implications. The lancet Diabetes & 
endocrinology 2013;1:152-162 
3. Ruderman NB, Berchtold P, Schneider S: Obesity-associated disorders in normal-
weight individuals: some speculations. Int J Obes 1982;6 Suppl 1:151-157 
4. Ruderman NB, Schneider SH, Berchtold P: The "metabolically-obese," normal-
weight individual. The American journal of clinical nutrition 1981;34:1617-1621 
5. Stefan N, Schick F, Haring HU: Causes, Characteristics, and Consequences of 
Metabolically Unhealthy Normal Weight in Humans. Cell metabolism 2017;26:292-
300 
6. Yaghootkar H, Lotta LA, Tyrrell J, Smit RA, Jones SE, Donnelly L, Beaumont R, 
Campbell A, Tuke MA, Hayward C, Ruth KS, Padmanabhan S, Jukema JW, Palmer 
CC, Hattersley A, Freathy RM, Langenberg C, Wareham NJ, Wood AR, Murray A, 
Weedon MN, Sattar N, Pearson E, Scott RA, Frayling TM: Genetic Evidence for a 
Link Between Favorable Adiposity and Lower Risk of Type 2 Diabetes, 
Hypertension, and Heart Disease. Diabetes 2016;65:2448-2460 
7. Yaghootkar H, Scott RA, White CC, Zhang W, Speliotes E, Munroe PB, Ehret GB, 
Bis JC, Fox CS, Walker M, Borecki IB, Knowles JW, Yerges-Armstrong L, Ohlsson 
C, Perry JR, Chambers JC, Kooner JS, Franceschini N, Langenberg C, Hivert MF, 
Dastani Z, Richards JB, Semple RK, Frayling TM: Genetic evidence for a normal-
weight "metabolically obese" phenotype linking insulin resistance, hypertension, 
coronary artery disease, and type 2 diabetes. Diabetes 2014;63:4369-4377 
8. Kilpelainen TO, Zillikens MC, Stancakova A, Finucane FM, Ried JS, Langenberg 
C, Zhang W, Beckmann JS, Luan J, Vandenput L, Styrkarsdottir U, Zhou Y, Smith 
AV, Zhao JH, Amin N, Vedantam S, Shin SY, Haritunians T, Fu M, Feitosa MF, 
Kumari M, Halldorsson BV, Tikkanen E, Mangino M, Hayward C, Song C, Arnold 
AM, Aulchenko YS, Oostra BA, Campbell H, Cupples LA, Davis KE, Doring A, 
Eiriksdottir G, Estrada K, Fernandez-Real JM, Garcia M, Gieger C, Glazer NL, 
Guiducci C, Hofman A, Humphries SE, Isomaa B, Jacobs LC, Jula A, Karasik D, 
Karlsson MK, Khaw KT, Kim LJ, Kivimaki M, Klopp N, Kuhnel B, Kuusisto J, Liu 
Y, Ljunggren O, Lorentzon M, Luben RN, McKnight B, Mellstrom D, Mitchell BD, 
Mooser V, Moreno JM, Mannisto S, O'Connell JR, Pascoe L, Peltonen L, Peral B, 
Perola M, Psaty BM, Salomaa V, Savage DB, Semple RK, Skaric-Juric T, Sigurdsson 
G, Song KS, Spector TD, Syvanen AC, Talmud PJ, Thorleifsson G, Thorsteinsdottir 
U, Uitterlinden AG, van Duijn CM, Vidal-Puig A, Wild SH, Wright AF, Clegg DJ, 
Schadt E, Wilson JF, Rudan I, Ripatti S, Borecki IB, Shuldiner AR, Ingelsson E, 
Jansson JO, Kaplan RC, Gudnason V, Harris TB, Groop L, Kiel DP, Rivadeneira F, 
Walker M, Barroso I, Vollenweider P, Waeber G, Chambers JC, Kooner JS, Soranzo 
N, Hirschhorn JN, Stefansson K, Wichmann HE, Ohlsson C, O'Rahilly S, Wareham 
NJ, Speliotes EK, Fox CS, Laakso M, Loos RJ: Genetic variation near IRS1 
associates with reduced adiposity and an impaired metabolic profile. Nature genetics 
2011;43:753-760 
9. Lotta LA, Gulati P, Day FR, Payne F, Ongen H, van de Bunt M, Gaulton KJ, 
Eicher JD, Sharp SJ, Luan J, De Lucia Rolfe E, Stewart ID, Wheeler E, Willems SM, 
Adams C, Yaghootkar H, Forouhi NG, Khaw KT, Johnson AD, Semple RK, Frayling 
T, Perry JR, Dermitzakis E, McCarthy MI, Barroso I, Wareham NJ, Savage DB, 
Page 33 of 96
Diabetes
 Langenberg C, O'Rahilly S, Scott RA: Integrative genomic analysis implicates limited 
peripheral adipose storage capacity in the pathogenesis of human insulin resistance. 
Nature genetics 2017;49:17-26 
10. Scott RA, Fall T, Pasko D, Barker A, Sharp SJ, Arriola L, Balkau B, Barricarte A, 
Barroso I, Boeing H, Clavel-Chapelon F, Crowe FL, Dekker JM, Fagherazzi G, 
Ferrannini E, Forouhi NG, Franks PW, Gavrila D, Giedraitis V, Grioni S, Groop LC, 
Kaaks R, Key TJ, Kuhn T, Lotta LA, Nilsson PM, Overvad K, Palli D, Panico S, 
Quiros JR, Rolandsson O, Roswall N, Sacerdote C, Sala N, Sanchez MJ, Schulze MB, 
Siddiq A, Slimani N, Sluijs I, Spijkerman AM, Tjonneland A, Tumino R, van der AD, 
Yaghootkar H, McCarthy MI, Semple RK, Riboli E, Walker M, Ingelsson E, Frayling 
TM, Savage DB, Langenberg C, Wareham NJ: Common genetic variants highlight 
the role of insulin resistance and body fat distribution in type 2 diabetes, independent 
of obesity. Diabetes 2014;63:4378-4387 
11. Gray SL, Vidal-Puig AJ: Adipose tissue expandability in the maintenance of 
metabolic homeostasis. Nutr Rev 2007;65:S7-12 
12. Roemmich JN, Rogol AD: Hormonal changes during puberty and their 
relationship to fat distribution. Am J Hum Biol 1999;11:209-224 
13. Collins R: What makes UK Biobank special? Lancet 2012;379:1173-1174 
14. Loh PR, Tucker G, Bulik-Sullivan BK, Vilhjalmsson BJ, Finucane HK, Salem 
RM, Chasman DI, Ridker PM, Neale BM, Berger B, Patterson N, Price AL: Efficient 
Bayesian mixed-model analysis increases association power in large cohorts. Nature 
genetics 2015;47:284-290 
15. Lu Y, Day FR, Gustafsson S, Buchkovich ML, Na J, Bataille V, Cousminer DL, 
Dastani Z, Drong AW, Esko T, Evans DM, Falchi M, Feitosa MF, Ferreira T, 
Hedman AK, Haring R, Hysi PG, Iles MM, Justice AE, Kanoni S, Lagou V, Li R, Li 
X, Locke A, Lu C, Magi R, Perry JR, Pers TH, Qi Q, Sanna M, Schmidt EM, Scott 
WR, Shungin D, Teumer A, Vinkhuyzen AA, Walker RW, Westra HJ, Zhang M, 
Zhang W, Zhao JH, Zhu Z, Afzal U, Ahluwalia TS, Bakker SJ, Bellis C, Bonnefond 
A, Borodulin K, Buchman AS, Cederholm T, Choh AC, Choi HJ, Curran JE, de Groot 
LC, De Jager PL, Dhonukshe-Rutten RA, Enneman AW, Eury E, Evans DS, Forsen 
T, Friedrich N, Fumeron F, Garcia ME, Gartner S, Han BG, Havulinna AS, Hayward 
C, Hernandez D, Hillege H, Ittermann T, Kent JW, Kolcic I, Laatikainen T, Lahti J, 
Mateo Leach I, Lee CG, Lee JY, Liu T, Liu Y, Lobbens S, Loh M, Lyytikainen LP, 
Medina-Gomez C, Michaelsson K, Nalls MA, Nielson CM, Oozageer L, Pascoe L, 
Paternoster L, Polasek O, Ripatti S, Sarzynski MA, Shin CS, Narancic NS, Spira D, 
Srikanth P, Steinhagen-Thiessen E, Sung YJ, Swart KM, Taittonen L, Tanaka T, 
Tikkanen E, van der Velde N, van Schoor NM, Verweij N, Wright AF, Yu L, Zmuda 
JM, Eklund N, Forrester T, Grarup N, Jackson AU, Kristiansson K, Kuulasmaa T, 
Kuusisto J, Lichtner P, Luan J, Mahajan A, Mannisto S, Palmer CD, Ried JS, Scott 
RA, Stancakova A, Wagner PJ, Demirkan A, Doring A, Gudnason V, Kiel DP, 
Kuhnel B, Mangino M, McKnight B, Menni C, O'Connell JR, Oostra BA, Shuldiner 
AR, Song K, Vandenput L, van Duijn CM, Vollenweider P, White CC, Boehnke M, 
Boettcher Y, Cooper RS, Forouhi NG, Gieger C, Grallert H, Hingorani A, Jorgensen 
T, Jousilahti P, Kivimaki M, Kumari M, Laakso M, Langenberg C, Linneberg A, 
Luke A, McKenzie CA, Palotie A, Pedersen O, Peters A, Strauch K, Tayo BO, 
Wareham NJ, Bennett DA, Bertram L, Blangero J, Bluher M, Bouchard C, Campbell 
H, Cho NH, Cummings SR, Czerwinski SA, Demuth I, Eckardt R, Eriksson JG, 
Ferrucci L, Franco OH, Froguel P, Gansevoort RT, Hansen T, Harris TB, Hastie N, 
Heliovaara M, Hofman A, Jordan JM, Jula A, Kahonen M, Kajantie E, Knekt PB, 
Koskinen S, Kovacs P, Lehtimaki T, Lind L, Liu Y, Orwoll ES, Osmond C, Perola M, 
Page 34 of 96
Diabetes
 Perusse L, Raitakari OT, Rankinen T, Rao DC, Rice TK, Rivadeneira F, Rudan I, 
Salomaa V, Sorensen TI, Stumvoll M, Tonjes A, Towne B, Tranah GJ, Tremblay A, 
Uitterlinden AG, van der Harst P, Vartiainen E, Viikari JS, Vitart V, Vohl MC, 
Volzke H, Walker M, Wallaschofski H, Wild S, Wilson JF, Yengo L, Bishop DT, 
Borecki IB, Chambers JC, Cupples LA, Dehghan A, Deloukas P, Fatemifar G, Fox C, 
Furey TS, Franke L, Han J, Hunter DJ, Karjalainen J, Karpe F, Kaplan RC, Kooner 
JS, McCarthy MI, Murabito JM, Morris AP, Bishop JA, North KE, Ohlsson C, Ong 
KK, Prokopenko I, Richards JB, Schadt EE, Spector TD, Widen E, Willer CJ, Yang J, 
Ingelsson E, Mohlke KL, Hirschhorn JN, Pospisilik JA, Zillikens MC, Lindgren C, 
Kilpelainen TO, Loos RJ: New loci for body fat percentage reveal link between 
adiposity and cardiometabolic disease risk. Nat Commun 2016;7:10495 
16. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki 
M, Pirruccello JP, Ripatti S, Chasman DI, Willer CJ, Johansen CT, Fouchier SW, 
Isaacs A, Peloso GM, Barbalic M, Ricketts SL, Bis JC, Aulchenko YS, Thorleifsson 
G, Feitosa MF, Chambers J, Orho-Melander M, Melander O, Johnson T, Li X, Guo 
X, Li M, Shin Cho Y, Jin Go M, Jin Kim Y, Lee JY, Park T, Kim K, Sim X, Twee-
Hee Ong R, Croteau-Chonka DC, Lange LA, Smith JD, Song K, Hua Zhao J, Yuan 
X, Luan J, Lamina C, Ziegler A, Zhang W, Zee RY, Wright AF, Witteman JC, 
Wilson JF, Willemsen G, Wichmann HE, Whitfield JB, Waterworth DM, Wareham 
NJ, Waeber G, Vollenweider P, Voight BF, Vitart V, Uitterlinden AG, Uda M, 
Tuomilehto J, Thompson JR, Tanaka T, Surakka I, Stringham HM, Spector TD, 
Soranzo N, Smit JH, Sinisalo J, Silander K, Sijbrands EJ, Scuteri A, Scott J, 
Schlessinger D, Sanna S, Salomaa V, Saharinen J, Sabatti C, Ruokonen A, Rudan I, 
Rose LM, Roberts R, Rieder M, Psaty BM, Pramstaller PP, Pichler I, Perola M, 
Penninx BW, Pedersen NL, Pattaro C, Parker AN, Pare G, Oostra BA, O'Donnell CJ, 
Nieminen MS, Nickerson DA, Montgomery GW, Meitinger T, McPherson R, 
McCarthy MI, McArdle W, Masson D, Martin NG, Marroni F, Mangino M, 
Magnusson PK, Lucas G, Luben R, Loos RJ, Lokki ML, Lettre G, Langenberg C, 
Launer LJ, Lakatta EG, Laaksonen R, Kyvik KO, Kronenberg F, Konig IR, Khaw 
KT, Kaprio J, Kaplan LM, Johansson A, Jarvelin MR, Janssens AC, Ingelsson E, Igl 
W, Kees Hovingh G, Hottenga JJ, Hofman A, Hicks AA, Hengstenberg C, Heid IM, 
Hayward C, Havulinna AS, Hastie ND, Harris TB, Haritunians T, Hall AS, 
Gyllensten U, Guiducci C, Groop LC, Gonzalez E, Gieger C, Freimer NB, Ferrucci L, 
Erdmann J, Elliott P, Ejebe KG, Doring A, Dominiczak AF, Demissie S, Deloukas P, 
de Geus EJ, de Faire U, Crawford G, Collins FS, Chen YD, Caulfield MJ, Campbell 
H, Burtt NP, Bonnycastle LL, Boomsma DI, Boekholdt SM, Bergman RN, Barroso I, 
Bandinelli S, Ballantyne CM, Assimes TL, Quertermous T, Altshuler D, Seielstad M, 
Wong TY, Tai ES, Feranil AB, Kuzawa CW, Adair LS, Taylor HA, Jr., Borecki IB, 
Gabriel SB, Wilson JG, Holm H, Thorsteinsdottir U, Gudnason V, Krauss RM, 
Mohlke KL, Ordovas JM, Munroe PB, Kooner JS, Tall AR, Hegele RA, Kastelein JJ, 
Schadt EE, Rotter JI, Boerwinkle E, Strachan DP, Mooser V, Stefansson K, Reilly 
MP, Samani NJ, Schunkert H, Cupples LA, Sandhu MS, Ridker PM, Rader DJ, van 
Duijn CM, Peltonen L, Abecasis GR, Boehnke M, Kathiresan S: Biological, clinical 
and population relevance of 95 loci for blood lipids. Nature 2010;466:707-713 
17. Dastani Z, Hivert MF, Timpson N, Perry JR, Yuan X, Scott RA, Henneman P, 
Heid IM, Kizer JR, Lyytikainen LP, Fuchsberger C, Tanaka T, Morris AP, Small K, 
Isaacs A, Beekman M, Coassin S, Lohman K, Qi L, Kanoni S, Pankow JS, Uh HW, 
Wu Y, Bidulescu A, Rasmussen-Torvik LJ, Greenwood CM, Ladouceur M, Grimsby 
J, Manning AK, Liu CT, Kooner J, Mooser VE, Vollenweider P, Kapur KA, 
Chambers J, Wareham NJ, Langenberg C, Frants R, Willems-Vandijk K, Oostra BA, 
Page 35 of 96
Diabetes
 Willems SM, Lamina C, Winkler TW, Psaty BM, Tracy RP, Brody J, Chen I, Viikari 
J, Kahonen M, Pramstaller PP, Evans DM, St Pourcain B, Sattar N, Wood AR, 
Bandinelli S, Carlson OD, Egan JM, Bohringer S, van Heemst D, Kedenko L, 
Kristiansson K, Nuotio ML, Loo BM, Harris T, Garcia M, Kanaya A, Haun M, Klopp 
N, Wichmann HE, Deloukas P, Katsareli E, Couper DJ, Duncan BB, Kloppenburg M, 
Adair LS, Borja JB, Wilson JG, Musani S, Guo X, Johnson T, Semple R, Teslovich 
TM, Allison MA, Redline S, Buxbaum SG, Mohlke KL, Meulenbelt I, Ballantyne 
CM, Dedoussis GV, Hu FB, Liu Y, Paulweber B, Spector TD, Slagboom PE, Ferrucci 
L, Jula A, Perola M, Raitakari O, Florez JC, Salomaa V, Eriksson JG, Frayling TM, 
Hicks AA, Lehtimaki T, Smith GD, Siscovick DS, Kronenberg F, van Duijn C, Loos 
RJ, Waterworth DM, Meigs JB, Dupuis J, Richards JB, Voight BF, Scott LJ, 
Steinthorsdottir V, Dina C, Welch RP, Zeggini E, Huth C, Aulchenko YS, 
Thorleifsson G, McCulloch LJ, Ferreira T, Grallert H, Amin N, Wu G, Willer CJ, 
Raychaudhuri S, McCarroll SA, Hofmann OM, Segre AV, van Hoek M, Navarro P, 
Ardlie K, Balkau B, Benediktsson R, Bennett AJ, Blagieva R, Boerwinkle E, 
Bonnycastle LL, Bostrom KB, Bravenboer B, Bumpstead S, Burtt NP, Charpentier G, 
Chines PS, Cornelis M, Crawford G, Doney AS, Elliott KS, Elliott AL, Erdos MR, 
Fox CS, Franklin CS, Ganser M, Gieger C, Grarup N, Green T, Griffin S, Groves CJ, 
Guiducci C, Hadjadj S, Hassanali N, Herder C, Isomaa B, Jackson AU, Johnson PR, 
Jorgensen T, Kao WH, Kong A, Kraft P, Kuusisto J, Lauritzen T, Li M, Lieverse A, 
Lindgren CM, Lyssenko V, Marre M, Meitinger T, Midthjell K, Morken MA, Narisu 
N, Nilsson P, Owen KR, Payne F, Petersen AK, Platou C, Proenca C, Prokopenko I, 
Rathmann W, Rayner NW, Robertson NR, Rocheleau G, Roden M, Sampson MJ, 
Saxena R, Shields BM, Shrader P, Sigurdsson G, Sparso T, Strassburger K, 
Stringham HM, Sun Q, Swift AJ, Thorand B, Tichet J, Tuomi T, van Dam RM, van 
Haeften TW, van Herpt T, van Vliet-Ostaptchouk JV, Walters GB, Weedon MN, 
Wijmenga C, Witteman J, Bergman RN, Cauchi S, Collins FS, Gloyn AL, Gyllensten 
U, Hansen T, Hide WA, Hitman GA, Hofman A, Hunter DJ, Hveem K, Laakso M, 
Morris AD, Palmer CN, Rudan I, Sijbrands E, Stein LD, Tuomilehto J, Uitterlinden 
A, Walker M, Watanabe RM, Abecasis GR, Boehm BO, Campbell H, Daly MJ, 
Hattersley AT, Pedersen O, Barroso I, Groop L, Sladek R, Thorsteinsdottir U, Wilson 
JF, Illig T, Froguel P, van Duijn CM, Stefansson K, Altshuler D, Boehnke M, 
McCarthy MI, Soranzo N, Wheeler E, Glazer NL, Bouatia-Naji N, Magi R, Randall J, 
Elliott P, Rybin D, Dehghan A, Hottenga JJ, Song K, Goel A, Lajunen T, Doney A, 
Cavalcanti-Proenca C, Kumari M, Timpson NJ, Zabena C, Ingelsson E, An P, 
O'Connell J, Luan J, Elliott A, McCarroll SA, Roccasecca RM, Pattou F, Sethupathy 
P, Ariyurek Y, Barter P, Beilby JP, Ben-Shlomo Y, Bergmann S, Bochud M, 
Bonnefond A, Borch-Johnsen K, Bottcher Y, Brunner E, Bumpstead SJ, Chen YD, 
Chines P, Clarke R, Coin LJ, Cooper MN, Crisponi L, Day IN, de Geus EJ, 
Delplanque J, Fedson AC, Fischer-Rosinsky A, Forouhi NG, Franzosi MG, Galan P, 
Goodarzi MO, Graessler J, Grundy S, Gwilliam R, Hallmans G, Hammond N, Han X, 
Hartikainen AL, Hayward C, Heath SC, Hercberg S, Hillman DR, Hingorani AD, Hui 
J, Hung J, Kaakinen M, Kaprio J, Kesaniemi YA, Kivimaki M, Knight B, Koskinen 
S, Kovacs P, Kyvik KO, Lathrop GM, Lawlor DA, Le Bacquer O, Lecoeur C, Li Y, 
Mahley R, Mangino M, Martinez-Larrad MT, McAteer JB, McPherson R, Meisinger 
C, Melzer D, Meyre D, Mitchell BD, Mukherjee S, Naitza S, Neville MJ, Orru M, 
Pakyz R, Paolisso G, Pattaro C, Pearson D, Peden JF, Pedersen NL, Pfeiffer AF, 
Pichler I, Polasek O, Posthuma D, Potter SC, Pouta A, Province MA, Rayner NW, 
Rice K, Ripatti S, Rivadeneira F, Rolandsson O, Sandbaek A, Sandhu M, Sanna S, 
Sayer AA, Scheet P, Seedorf U, Sharp SJ, Shields B, Sigurethsson G, Sijbrands EJ, 
Page 36 of 96
Diabetes
 Silveira A, Simpson L, Singleton A, Smith NL, Sovio U, Swift A, Syddall H, 
Syvanen AC, Tonjes A, Uitterlinden AG, van Dijk KW, Varma D, Visvikis-Siest S, 
Vitart V, Vogelzangs N, Waeber G, Wagner PJ, Walley A, Ward KL, Watkins H, 
Wild SH, Willemsen G, Witteman JC, Yarnell JW, Zelenika D, Zethelius B, Zhai G, 
Zhao JH, Zillikens MC, Borecki IB, Meneton P, Magnusson PK, Nathan DM, 
Williams GH, Silander K, Bornstein SR, Schwarz P, Spranger J, Karpe F, Shuldiner 
AR, Cooper C, Serrano-Rios M, Lind L, Palmer LJ, Hu FBs, Franks PW, Ebrahim S, 
Marmot M, Kao WH, Pramstaller PP, Wright AF, Stumvoll M, Hamsten A, Buchanan 
TA, Valle TT, Rotter JI, Penninx BW, Boomsma DI, Cao A, Scuteri A, Schlessinger 
D, Uda M, Ruokonen A, Jarvelin MR, Peltonen L, Mooser V, Sladek R, Musunuru K, 
Smith AV, Edmondson AC, Stylianou IM, Koseki M, Pirruccello JP, Chasman DI, 
Johansen CT, Fouchier SW, Peloso GM, Barbalic M, Ricketts SL, Bis JC, Feitosa 
MF, Orho-Melander M, Melander O, Li X, Li M, Cho YS, Go MJ, Kim YJ, Lee JY, 
Park T, Kim K, Sim X, Ong RT, Croteau-Chonka DC, Lange LA, Smith JD, Ziegler 
A, Zhang W, Zee RY, Whitfield JB, Thompson JR, Surakka I, Spector TD, Smit JH, 
Sinisalo J, Scott J, Saharinen J, Sabatti C, Rose LM, Roberts R, Rieder M, Parker AN, 
Pare G, O'Donnell CJ, Nieminen MS, Nickerson DA, Montgomery GW, McArdle W, 
Masson D, Martin NG, Marroni F, Lucas G, Luben R, Lokki ML, Lettre G, Launer 
LJ, Lakatta EG, Laaksonen R, Kyvik KO, Konig IR, Khaw KT, Kaplan LM, 
Johansson A, Janssens AC, Igl W, Hovingh GK, Hengstenberg C, Havulinna AS, 
Hastie ND, Harris TB, Haritunians T, Hall AS, Groop LC, Gonzalez E, Freimer NB, 
Erdmann J, Ejebe KG, Doring A, Dominiczak AF, Demissie S, Deloukas P, de Faire 
U, Crawford G, Chen YD, Caulfield MJ, Boekholdt SM, Assimes TL, Quertermous 
T, Seielstad M, Wong TY, Tai ES, Feranil AB, Kuzawa CW, Taylor HA, Jr., Gabriel 
SB, Holm H, Gudnason V, Krauss RM, Ordovas JM, Munroe PB, Kooner JS, Tall 
AR, Hegele RA, Kastelein JJ, Schadt EE, Strachan DP, Reilly MP, Samani NJ, 
Schunkert H, Cupples LA, Sandhu MS, Ridker PM, Rader DJ, Kathiresan S: Novel 
loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: 
a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet 2012;8:e1002607 
18. Coviello AD, Haring R, Wellons M, Vaidya D, Lehtimaki T, Keildson S, Lunetta 
KL, He C, Fornage M, Lagou V, Mangino M, Onland-Moret NC, Chen B, Eriksson J, 
Garcia M, Liu YM, Koster A, Lohman K, Lyytikainen LP, Petersen AK, Prescott J, 
Stolk L, Vandenput L, Wood AR, Zhuang WV, Ruokonen A, Hartikainen AL, Pouta 
A, Bandinelli S, Biffar R, Brabant G, Cox DG, Chen Y, Cummings S, Ferrucci L, 
Gunter MJ, Hankinson SE, Martikainen H, Hofman A, Homuth G, Illig T, Jansson 
JO, Johnson AD, Karasik D, Karlsson M, Kettunen J, Kiel DP, Kraft P, Liu J, 
Ljunggren O, Lorentzon M, Maggio M, Markus MR, Mellstrom D, Miljkovic I, Mirel 
D, Nelson S, Morin Papunen L, Peeters PH, Prokopenko I, Raffel L, Reincke M, 
Reiner AP, Rexrode K, Rivadeneira F, Schwartz SM, Siscovick D, Soranzo N, Stockl 
D, Tworoger S, Uitterlinden AG, van Gils CH, Vasan RS, Wichmann HE, Zhai G, 
Bhasin S, Bidlingmaier M, Chanock SJ, De Vivo I, Harris TB, Hunter DJ, Kahonen 
M, Liu S, Ouyang P, Spector TD, van der Schouw YT, Viikari J, Wallaschofski H, 
McCarthy MI, Frayling TM, Murray A, Franks S, Jarvelin MR, de Jong FH, Raitakari 
O, Teumer A, Ohlsson C, Murabito JM, Perry JR: A genome-wide association meta-
analysis of circulating sex hormone-binding globulin reveals multiple Loci implicated 
in sex steroid hormone regulation. PLoS Genet 2012;8:e1002805 
19. Manning AK, Hivert MF, Scott RA, Grimsby JL, Bouatia-Naji N, Chen H, Rybin 
D, Liu CT, Bielak LF, Prokopenko I, Amin N, Barnes D, Cadby G, Hottenga JJ, 
Ingelsson E, Jackson AU, Johnson T, Kanoni S, Ladenvall C, Lagou V, Lahti J, 
Lecoeur C, Liu Y, Martinez-Larrad MT, Montasser ME, Navarro P, Perry JR, 
Page 37 of 96
Diabetes
 Rasmussen-Torvik LJ, Salo P, Sattar N, Shungin D, Strawbridge RJ, Tanaka T, van 
Duijn CM, An P, de Andrade M, Andrews JS, Aspelund T, Atalay M, Aulchenko Y, 
Balkau B, Bandinelli S, Beckmann JS, Beilby JP, Bellis C, Bergman RN, Blangero J, 
Boban M, Boehnke M, Boerwinkle E, Bonnycastle LL, Boomsma DI, Borecki IB, 
Bottcher Y, Bouchard C, Brunner E, Budimir D, Campbell H, Carlson O, Chines PS, 
Clarke R, Collins FS, Corbaton-Anchuelo A, Couper D, de Faire U, Dedoussis GV, 
Deloukas P, Dimitriou M, Egan JM, Eiriksdottir G, Erdos MR, Eriksson JG, Eury E, 
Ferrucci L, Ford I, Forouhi NG, Fox CS, Franzosi MG, Franks PW, Frayling TM, 
Froguel P, Galan P, de Geus E, Gigante B, Glazer NL, Goel A, Groop L, Gudnason 
V, Hallmans G, Hamsten A, Hansson O, Harris TB, Hayward C, Heath S, Hercberg S, 
Hicks AA, Hingorani A, Hofman A, Hui J, Hung J, Jarvelin MR, Jhun MA, Johnson 
PC, Jukema JW, Jula A, Kao WH, Kaprio J, Kardia SL, Keinanen-Kiukaanniemi S, 
Kivimaki M, Kolcic I, Kovacs P, Kumari M, Kuusisto J, Kyvik KO, Laakso M, Lakka 
T, Lannfelt L, Lathrop GM, Launer LJ, Leander K, Li G, Lind L, Lindstrom J, 
Lobbens S, Loos RJ, Luan J, Lyssenko V, Magi R, Magnusson PK, Marmot M, 
Meneton P, Mohlke KL, Mooser V, Morken MA, Miljkovic I, Narisu N, O'Connell J, 
Ong KK, Oostra BA, Palmer LJ, Palotie A, Pankow JS, Peden JF, Pedersen NL, 
Pehlic M, Peltonen L, Penninx B, Pericic M, Perola M, Perusse L, Peyser PA, Polasek 
O, Pramstaller PP, Province MA, Raikkonen K, Rauramaa R, Rehnberg E, Rice K, 
Rotter JI, Rudan I, Ruokonen A, Saaristo T, Sabater-Lleal M, Salomaa V, Savage DB, 
Saxena R, Schwarz P, Seedorf U, Sennblad B, Serrano-Rios M, Shuldiner AR, 
Sijbrands EJ, Siscovick DS, Smit JH, Small KS, Smith NL, Smith AV, Stancakova A, 
Stirrups K, Stumvoll M, Sun YV, Swift AJ, Tonjes A, Tuomilehto J, Trompet S, 
Uitterlinden AG, Uusitupa M, Vikstrom M, Vitart V, Vohl MC, Voight BF, 
Vollenweider P, Waeber G, Waterworth DM, Watkins H, Wheeler E, Widen E, Wild 
SH, Willems SM, Willemsen G, Wilson JF, Witteman JC, Wright AF, Yaghootkar H, 
Zelenika D, Zemunik T, Zgaga L, Wareham NJ, McCarthy MI, Barroso I, Watanabe 
RM, Florez JC, Dupuis J, Meigs JB, Langenberg C: A genome-wide approach 
accounting for body mass index identifies genetic variants influencing fasting 
glycemic traits and insulin resistance. Nature genetics 2012;44:659-669 
20. Chambers JC, Zhang W, Sehmi J, Li X, Wass MN, Van der Harst P, Holm H, 
Sanna S, Kavousi M, Baumeister SE, Coin LJ, Deng G, Gieger C, Heard-Costa NL, 
Hottenga JJ, Kuhnel B, Kumar V, Lagou V, Liang L, Luan J, Vidal PM, Mateo Leach 
I, O'Reilly PF, Peden JF, Rahmioglu N, Soininen P, Speliotes EK, Yuan X, 
Thorleifsson G, Alizadeh BZ, Atwood LD, Borecki IB, Brown MJ, Charoen P, Cucca 
F, Das D, de Geus EJ, Dixon AL, Doring A, Ehret G, Eyjolfsson GI, Farrall M, 
Forouhi NG, Friedrich N, Goessling W, Gudbjartsson DF, Harris TB, Hartikainen 
AL, Heath S, Hirschfield GM, Hofman A, Homuth G, Hypponen E, Janssen HL, 
Johnson T, Kangas AJ, Kema IP, Kuhn JP, Lai S, Lathrop M, Lerch MM, Li Y, Liang 
TJ, Lin JP, Loos RJ, Martin NG, Moffatt MF, Montgomery GW, Munroe PB, 
Musunuru K, Nakamura Y, O'Donnell CJ, Olafsson I, Penninx BW, Pouta A, Prins 
BP, Prokopenko I, Puls R, Ruokonen A, Savolainen MJ, Schlessinger D, Schouten 
JN, Seedorf U, Sen-Chowdhry S, Siminovitch KA, Smit JH, Spector TD, Tan W, 
Teslovich TM, Tukiainen T, Uitterlinden AG, Van der Klauw MM, Vasan RS, 
Wallace C, Wallaschofski H, Wichmann HE, Willemsen G, Wurtz P, Xu C, Yerges-
Armstrong LM, Abecasis GR, Ahmadi KR, Boomsma DI, Caulfield M, Cookson 
WO, van Duijn CM, Froguel P, Matsuda K, McCarthy MI, Meisinger C, Mooser V, 
Pietilainen KH, Schumann G, Snieder H, Sternberg MJ, Stolk RP, Thomas HC, 
Thorsteinsdottir U, Uda M, Waeber G, Wareham NJ, Waterworth DM, Watkins H, 
Whitfield JB, Witteman JC, Wolffenbuttel BH, Fox CS, Ala-Korpela M, Stefansson 
Page 38 of 96
Diabetes
 K, Vollenweider P, Volzke H, Schadt EE, Scott J, Jarvelin MR, Elliott P, Kooner JS: 
Genome-wide association study identifies loci influencing concentrations of liver 
enzymes in plasma. Nature genetics 2011;43:1131-1138 
21. Semple RK, Savage DB, Cochran EK, Gorden P, O'Rahilly S: Genetic syndromes 
of severe insulin resistance. Endocrine reviews 2011;32:498-514 
22. Stears A, O'Rahilly S, Semple RK, Savage DB: Metabolic insights from extreme 
human insulin resistance phenotypes. Best practice & research Clinical endocrinology 
& metabolism 2012;26:145-157 
23. Cichonska A, Rousu J, Marttinen P, Kangas AJ, Soininen P, Lehtimaki T, 
Raitakari OT, Jarvelin MR, Salomaa V, Ala-Korpela M, Ripatti S, Pirinen M: 
metaCCA: summary statistics-based multivariate meta-analysis of genome-wide 
association 
studies 
using 
canonical 
correlation 
analysis. 
Bioinformatics 
2016;32:1981-1989 
24. de Mutsert R, den Heijer M, Rabelink TJ, Smit JW, Romijn JA, Jukema JW, de 
Roos A, Cobbaert CM, Kloppenburg M, le Cessie S, Middeldorp S, Rosendaal FR: 
The Netherlands Epidemiology of Obesity (NEO) study: study design and data 
collection. Eur J Epidemiol 2013;28:513-523 
25. Smith BH, Campbell A, Linksted P, Fitzpatrick B, Jackson C, Kerr SM, Deary IJ, 
Macintyre DJ, Campbell H, McGilchrist M, Hocking LJ, Wisely L, Ford I, Lindsay 
RS, Morton R, Palmer CN, Dominiczak AF, Porteous DJ, Morris AD: Cohort Profile: 
Generation Scotland: Scottish Family Health Study (GS:SFHS). The study, its 
participants and their potential for genetic research on health and illness. Int J 
Epidemiol 2013;42:689-700 
26. Machann J, Thamer C, Stefan N, Schwenzer NF, Kantartzis K, Haring HU, 
Claussen CD, Fritsche A, Schick F: Follow-up whole-body assessment of adipose 
tissue compartments during a lifestyle intervention in a large cohort at increased risk 
for type 2 diabetes. Radiology 2010;257:353-363 
27. Koivula RW, Heggie A, Barnett A, Cederberg H, Hansen TH, Koopman AD, 
Ridderstrale M, Rutters F, Vestergaard H, Gupta R, Herrgard S, Heymans MW, Perry 
MH, Rauh S, Siloaho M, Teare HJ, Thorand B, Bell J, Brunak S, Frost G, Jablonka B, 
Mari A, McDonald TJ, Dekker JM, Hansen T, Hattersley A, Laakso M, Pedersen O, 
Koivisto V, Ruetten H, Walker M, Pearson E, Franks PW: Discovery of biomarkers 
for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and 
design of the epidemiological studies within the IMI DIRECT Consortium. 
Diabetologia 2014;57:1132-1142 
28. Mahajan A, Go MJ, Zhang W, Below JE, Gaulton KJ, Ferreira T, Horikoshi M, 
Johnson AD, Ng MC, Prokopenko I, Saleheen D, Wang X, Zeggini E, Abecasis GR, 
Adair LS, Almgren P, Atalay M, Aung T, Baldassarre D, Balkau B, Bao Y, Barnett 
AH, Barroso I, Basit A, Been LF, Beilby J, Bell GI, Benediktsson R, Bergman RN, 
Boehm BO, Boerwinkle E, Bonnycastle LL, Burtt N, Cai Q, Campbell H, Carey J, 
Cauchi S, Caulfield M, Chan JC, Chang LC, Chang TJ, Chang YC, Charpentier G, 
Chen CH, Chen H, Chen YT, Chia KS, Chidambaram M, Chines PS, Cho NH, Cho 
YM, Chuang LM, Collins FS, Cornelis MC, Couper DJ, Crenshaw AT, van Dam RM, 
Danesh J, Das D, de Faire U, Dedoussis G, Deloukas P, Dimas AS, Dina C, Doney 
AS, Donnelly PJ, Dorkhan M, van Duijn C, Dupuis J, Edkins S, Elliott P, Emilsson 
V, Erbel R, Eriksson JG, Escobedo J, Esko T, Eury E, Florez JC, Fontanillas P, 
Forouhi NG, Forsen T, Fox C, Fraser RM, Frayling TM, Froguel P, Frossard P, Gao 
Y, Gertow K, Gieger C, Gigante B, Grallert H, Grant GB, Grrop LC, Groves CJ, 
Grundberg E, Guiducci C, Hamsten A, Han BG, Hara K, Hassanali N, Hattersley AT, 
Hayward C, Hedman AK, Herder C, Hofman A, Holmen OL, Hovingh K, 
Page 39 of 96
Diabetes
 Hreidarsson AB, Hu C, Hu FB, Hui J, Humphries SE, Hunt SE, Hunter DJ, Hveem K, 
Hydrie ZI, Ikegami H, Illig T, Ingelsson E, Islam M, Isomaa B, Jackson AU, Jafar T, 
James A, Jia W, Jockel KH, Jonsson A, Jowett JB, Kadowaki T, Kang HM, Kanoni S, 
Kao WH, Kathiresan S, Kato N, Katulanda P, Keinanen-Kiukaanniemi KM, Kelly 
AM, Khan H, Khaw KT, Khor CC, Kim HL, Kim S, Kim YJ, Kinnunen L, Klopp N, 
Kong A, Korpi-Hyovalti E, Kowlessur S, Kraft P, Kravic J, Kristensen MM, Krithika 
S, Kumar A, Kumate J, Kuusisto J, Kwak SH, Laakso M, Lagou V, Lakka TA, 
Langenberg C, Langford C, Lawrence R, Leander K, Lee JM, Lee NR, Li M, Li X, Li 
Y, Liang J, Liju S, Lim WY, Lind L, Lindgren CM, Lindholm E, Liu CT, Liu JJ, 
Lobbens S, Long J, Loos RJ, Lu W, Luan J, Lyssenko V, Ma RC, Maeda S, Magi R, 
Mannisto S, Matthews DR, Meigs JB, Melander O, Metspalu A, Meyer J, Mirza G, 
Mihailov E, Moebus S, Mohan V, Mohlke KL, Morris AD, Muhleisen TW, Muller-
Nurasyid M, Musk B, Nakamura J, Nakashima E, Navarro P, Ng PK, Nica AC, 
Nilsson PM, Njolstad I, Nothen MM, Ohnaka K, Ong TH, Owen KR, Palmer CN, 
Pankow JS, Park KS, Parkin M, Pechlivanis S, Pedersen NL, Peltonen L, Perry JR, 
Peters A, Pinidiyapathirage JM, Platou CG, Potter S, Price JF, Qi L, Radha V, 
Rallidis L, Rasheed A, Rathman W, Rauramaa R, Raychaudhuri S, Rayner NW, Rees 
SD, Rehnberg E, Ripatti S, Robertson N, Roden M, Rossin EJ, Rudan I, Rybin D, 
Saaristo TE, Salomaa V, Saltevo J, Samuel M, Sanghera DK, Saramies J, Scott J, 
Scott LJ, Scott RA, Segre AV, Sehmi J, Sennblad B, Shah N, Shah S, Shera AS, Shu 
XO, Shuldiner AR, Sigurdsson G, Sijbrands E, Silveira A, Sim X, Sivapalaratnam S, 
Small KS, So WY, Stancakova A, Stefansson K, Steinbach G, Steinthorsdottir V, 
Stirrups K, Strawbridge RJ, Stringham HM, Sun Q, Suo C, Syvanen AC, Takayanagi 
R, Takeuchi F, Tay WT, Teslovich TM, Thorand B, Thorleifsson G, Thorsteinsdottir 
U, Tikkanen E, Trakalo J, Tremoli E, Trip MD, Tsai FJ, Tuomi T, Tuomilehto J, 
Uitterlinden AG, Valladares-Salgado A, Vedantam S, Veglia F, Voight BF, Wang C, 
Wareham NJ, Wennauer R, Wickremasinghe AR, Wilsgaard T, Wilson JF, Wiltshire 
S, Winckler W, Wong TY, Wood AR, Wu JY, Wu Y, Yamamoto K, Yamauchi T, 
Yang M, Yengo L, Yokota M, Young R, Zabaneh D, Zhang F, Zhang R, Zheng W, 
Zimmet PZ, Altshuler D, Bowden DW, Cho YS, Cox NJ, Cruz M, Hanis CL, Kooner 
J, Lee JY, Seielstad M, Teo YY, Boehnke M, Parra EJ, Chambers JC, Tai ES, 
McCarthy MI, Morris AP: Genome-wide trans-ancestry meta-analysis provides 
insight into the genetic architecture of type 2 diabetes susceptibility. Nature genetics 
2014;46:234-244 
29. Nikpay M, Goel A, Won HH, Hall LM, Willenborg C, Kanoni S, Saleheen D, 
Kyriakou T, Nelson CP, Hopewell JC, Webb TR, Zeng L, Dehghan A, Alver M, 
Armasu SM, Auro K, Bjonnes A, Chasman DI, Chen S, Ford I, Franceschini N, 
Gieger C, Grace C, Gustafsson S, Huang J, Hwang SJ, Kim YK, Kleber ME, Lau 
KW, Lu X, Lu Y, Lyytikainen LP, Mihailov E, Morrison AC, Pervjakova N, Qu L, 
Rose LM, Salfati E, Saxena R, Scholz M, Smith AV, Tikkanen E, Uitterlinden A, 
Yang X, Zhang W, Zhao W, de Andrade M, de Vries PS, van Zuydam NR, Anand SS, 
Bertram L, Beutner F, Dedoussis G, Frossard P, Gauguier D, Goodall AH, Gottesman 
O, Haber M, Han BG, Huang J, Jalilzadeh S, Kessler T, Konig IR, Lannfelt L, Lieb 
W, Lind L, Lindgren CM, Lokki ML, Magnusson PK, Mallick NH, Mehra N, 
Meitinger T, Memon FU, Morris AP, Nieminen MS, Pedersen NL, Peters A, Rallidis 
LS, Rasheed A, Samuel M, Shah SH, Sinisalo J, Stirrups KE, Trompet S, Wang L, 
Zaman KS, Ardissino D, Boerwinkle E, Borecki IB, Bottinger EP, Buring JE, 
Chambers JC, Collins R, Cupples LA, Danesh J, Demuth I, Elosua R, Epstein SE, 
Esko T, Feitosa MF, Franco OH, Franzosi MG, Granger CB, Gu D, Gudnason V, Hall 
AS, Hamsten A, Harris TB, Hazen SL, Hengstenberg C, Hofman A, Ingelsson E, 
Page 40 of 96
Diabetes
 Iribarren C, Jukema JW, Karhunen PJ, Kim BJ, Kooner JS, Kullo IJ, Lehtimaki T, 
Loos RJF, Melander O, Metspalu A, Marz W, Palmer CN, Perola M, Quertermous T, 
Rader DJ, Ridker PM, Ripatti S, Roberts R, Salomaa V, Sanghera DK, Schwartz SM, 
Seedorf U, Stewart AF, Stott DJ, Thiery J, Zalloua PA, O'Donnell CJ, Reilly MP, 
Assimes TL, Thompson JR, Erdmann J, Clarke R, Watkins H, Kathiresan S, 
McPherson R, Deloukas P, Schunkert H, Samani NJ, Farrall M: A comprehensive 
1,000 Genomes-based genome-wide association meta-analysis of coronary artery 
disease. Nature genetics 2015;47:1121-1130 
30. Wain LV, Vaez A, Jansen R, Joehanes R, van der Most PJ, Erzurumluoglu AM, 
O'Reilly PF, Cabrera CP, Warren HR, Rose LM, Verwoert GC, Hottenga JJ, 
Strawbridge RJ, Esko T, Arking DE, Hwang SJ, Guo X, Kutalik Z, Trompet S, Shrine 
N, Teumer A, Ried JS, Bis JC, Smith AV, Amin N, Nolte IM, Lyytikainen LP, 
Mahajan A, Wareham NJ, Hofer E, Joshi PK, Kristiansson K, Traglia M, Havulinna 
AS, Goel A, Nalls MA, Sober S, Vuckovic D, Luan J, Del Greco MF, Ayers KL, 
Marrugat J, Ruggiero D, Lopez LM, Niiranen T, Enroth S, Jackson AU, Nelson CP, 
Huffman JE, Zhang W, Marten J, Gandin I, Harris SE, Zemunik T, Lu Y, Evangelou 
E, Shah N, de Borst MH, Mangino M, Prins BP, Campbell A, Li-Gao R, Chauhan G, 
Oldmeadow C, Abecasis G, Abedi M, Barbieri CM, Barnes MR, Batini C, Beilby J, 
Blake T, Boehnke M, Bottinger EP, Braund PS, Brown M, Brumat M, Campbell H, 
Chambers JC, Cocca M, Collins F, Connell J, Cordell HJ, Damman JJ, Davies G, de 
Geus EJ, de Mutsert R, Deelen J, Demirkale Y, Doney ASF, Dorr M, Farrall M, 
Ferreira T, Franberg M, Gao H, Giedraitis V, Gieger C, Giulianini F, Gow AJ, 
Hamsten A, Harris TB, Hofman A, Holliday EG, Hui J, Jarvelin MR, Johansson A, 
Johnson AD, Jousilahti P, Jula A, Kahonen M, Kathiresan S, Khaw KT, Kolcic I, 
Koskinen S, Langenberg C, Larson M, Launer LJ, Lehne B, Liewald DCM, Lin L, 
Lind L, Mach F, Mamasoula C, Menni C, Mifsud B, Milaneschi Y, Morgan A, Morris 
AD, Morrison AC, Munson PJ, Nandakumar P, Nguyen QT, Nutile T, Oldehinkel AJ, 
Oostra BA, Org E, Padmanabhan S, Palotie A, Pare G, Pattie A, Penninx B, Poulter 
N, Pramstaller PP, Raitakari OT, Ren M, Rice K, Ridker PM, Riese H, Ripatti S, 
Robino A, Rotter JI, Rudan I, Saba Y, Saint Pierre A, Sala CF, Sarin AP, Schmidt R, 
Scott R, Seelen MA, Shields DC, Siscovick D, Sorice R, Stanton A, Stott DJ, 
Sundstrom J, Swertz M, Taylor KD, Thom S, Tzoulaki I, Tzourio C, Uitterlinden AG, 
Volker U, Vollenweider P, Wild S, Willemsen G, Wright AF, Yao J, Theriault S, 
Conen D, Attia J, Sever P, Debette S, Mook-Kanamori DO, Zeggini E, Spector TD, 
van der Harst P, Palmer CNA, Vergnaud AC, Loos RJF, Polasek O, Starr JM, Girotto 
G, Hayward C, Kooner JS, Lindgren CM, Vitart V, Samani NJ, Tuomilehto J, 
Gyllensten U, Knekt P, Deary IJ, Ciullo M, Elosua R, Keavney BD, Hicks AA, Scott 
RA, Gasparini P, Laan M, Liu Y, Watkins H, Hartman CA, Salomaa V, Toniolo D, 
Perola M, Wilson JF, Schmidt H, Zhao JH, Lehtimaki T, van Duijn CM, Gudnason V, 
Psaty BM, Peters A, Rettig R, James A, Jukema JW, Strachan DP, Palmas W, 
Metspalu A, Ingelsson E, Boomsma DI, Franco OH, Bochud M, Newton-Cheh C, 
Munroe PB, Elliott P, Chasman DI, Chakravarti A, Knight J, Morris AP, Levy D, 
Tobin MD, Snieder H, Caulfield MJ, Ehret GB: Novel Blood Pressure Locus and 
Gene Discovery Using Genome-Wide Association Study and Expression Data Sets 
From Blood and the Kidney. Hypertension 2017; 
31. Wilman HR, Kelly M, Garratt S, Matthews PM, Milanesi M, Herlihy A, Gyngell 
M, Neubauer S, Bell JD, Banerjee R, Thomas EL: Characterisation of liver fat in the 
UK Biobank cohort. PloS one 2017;12:e0172921 
Page 41 of 96
Diabetes
 32. Linge J, Borga M, West J, Tuthill T, Miller MR, Dumitriu A, Thomas EL, Romu 
T, Tunon P, Bell JD, Dahlqvist Leinhard O: Body Composition Profiling in the UK 
Biobank Imaging Study. Obesity (Silver Spring, Md) 2018; 
33. West J, Dahlqvist Leinhard O, Romu T, Collins R, Garratt S, Bell JD, Borga M, 
Thomas L: Feasibility of MR-Based Body Composition Analysis in Large Scale 
Population Studies. PloS one 2016;11:e0163332 
34. Thomas EL, Fitzpatrick JA, Malik SJ, Taylor-Robinson SD, Bell JD: Whole body 
fat: content and distribution. Prog Nucl Magn Reson Spectrosc 2013;73:56-80 
35. Chu AY, Deng X, Fisher VA, Drong A, Zhang Y, Feitosa MF, Liu CT, Weeks O, 
Choh AC, Duan Q, Dyer TD, Eicher JD, Guo X, Heard-Costa NL, Kacprowski T, 
Kent JW, Jr., Lange LA, Liu X, Lohman K, Lu L, Mahajan A, O'Connell JR, Parihar 
A, Peralta JM, Smith AV, Zhang Y, Homuth G, Kissebah AH, Kullberg J, Laqua R, 
Launer LJ, Nauck M, Olivier M, Peyser PA, Terry JG, Wojczynski MK, Yao J, 
Bielak LF, Blangero J, Borecki IB, Bowden DW, Carr JJ, Czerwinski SA, Ding J, 
Friedrich N, Gudnason V, Harris TB, Ingelsson E, Johnson AD, Kardia SL, Langefeld 
CD, Lind L, Liu Y, Mitchell BD, Morris AP, Mosley TH, Jr., Rotter JI, Shuldiner AR, 
Towne B, Volzke H, Wallaschofski H, Wilson JG, Allison M, Lindgren CM, 
Goessling W, Cupples LA, Steinhauser ML, Fox CS: Multiethnic genome-wide meta-
analysis of ectopic fat depots identifies loci associated with adipocyte development 
and differentiation. Nature genetics 2017;49:125-130 
36. Shungin D, Winkler TW, Croteau-Chonka DC, Ferreira T, Locke AE, Magi R, 
Strawbridge RJ, Pers TH, Fischer K, Justice AE, Workalemahu T, Wu JMW, 
Buchkovich ML, Heard-Costa NL, Roman TS, Drong AW, Song C, Gustafsson S, 
Day FR, Esko T, Fall T, Kutalik Z, Luan J, Randall JC, Scherag A, Vedantam S, 
Wood AR, Chen J, Fehrmann R, Karjalainen J, Kahali B, Liu CT, Schmidt EM, 
Absher D, Amin N, Anderson D, Beekman M, Bragg-Gresham JL, Buyske S, 
Demirkan A, Ehret GB, Feitosa MF, Goel A, Jackson AU, Johnson T, Kleber ME, 
Kristiansson K, Mangino M, Leach IM, Medina-Gomez C, Palmer CD, Pasko D, 
Pechlivanis S, Peters MJ, Prokopenko I, Stancakova A, Sung YJ, Tanaka T, Teumer 
A, Van Vliet-Ostaptchouk JV, Yengo L, Zhang W, Albrecht E, Arnlov J, Arscott GM, 
Bandinelli S, Barrett A, Bellis C, Bennett AJ, Berne C, Bluher M, Bohringer S, 
Bonnet F, Bottcher Y, Bruinenberg M, Carba DB, Caspersen IH, Clarke R, Daw EW, 
Deelen J, Deelman E, Delgado G, Doney AS, Eklund N, Erdos MR, Estrada K, Eury 
E, Friedrich N, Garcia ME, Giedraitis V, Gigante B, Go AS, Golay A, Grallert H, 
Grammer TB, Grassler J, Grewal J, Groves CJ, Haller T, Hallmans G, Hartman CA, 
Hassinen M, Hayward C, Heikkila K, Herzig KH, Helmer Q, Hillege HL, Holmen O, 
Hunt SC, Isaacs A, Ittermann T, James AL, Johansson I, Juliusdottir T, Kalafati IP, 
Kinnunen L, Koenig W, Kooner IK, Kratzer W, Lamina C, Leander K, Lee NR, 
Lichtner P, Lind L, Lindstrom J, Lobbens S, Lorentzon M, Mach F, Magnusson PK, 
Mahajan A, McArdle WL, Menni C, Merger S, Mihailov E, Milani L, Mills R, 
Moayyeri A, Monda KL, Mooijaart SP, Muhleisen TW, Mulas A, Muller G, Muller-
Nurasyid M, Nagaraja R, Nalls MA, Narisu N, Glorioso N, Nolte IM, Olden M, 
Rayner NW, Renstrom F, Ried JS, Robertson NR, Rose LM, Sanna S, Scharnagl H, 
Scholtens S, Sennblad B, Seufferlein T, Sitlani CM, Smith AV, Stirrups K, Stringham 
HM, Sundstrom J, Swertz MA, Swift AJ, Syvanen AC, Tayo BO, Thorand B, 
Thorleifsson G, Tomaschitz A, Troffa C, van Oort FV, Verweij N, Vonk JM, Waite 
LL, Wennauer R, Wilsgaard T, Wojczynski MK, Wong A, Zhang Q, Zhao JH, 
Brennan EP, Choi M, Eriksson P, Folkersen L, Franco-Cereceda A, Gharavi AG, 
Hedman AK, Hivert MF, Huang J, Kanoni S, Karpe F, Keildson S, Kiryluk K, Liang 
L, Lifton RP, Ma B, McKnight AJ, McPherson R, Metspalu A, Min JL, Moffatt MF, 
Page 42 of 96
Diabetes
 Montgomery GW, Murabito JM, Nicholson G, Nyholt DR, Olsson C, Perry JR, 
Reinmaa E, Salem RM, Sandholm N, Schadt EE, Scott RA, Stolk L, Vallejo EE, 
Westra HJ, Zondervan KT, Amouyel P, Arveiler D, Bakker SJ, Beilby J, Bergman 
RN, Blangero J, Brown MJ, Burnier M, Campbell H, Chakravarti A, Chines PS, 
Claudi-Boehm S, Collins FS, Crawford DC, Danesh J, de Faire U, de Geus EJ, Dorr 
M, Erbel R, Eriksson JG, Farrall M, Ferrannini E, Ferrieres J, Forouhi NG, Forrester 
T, Franco OH, Gansevoort RT, Gieger C, Gudnason V, Haiman CA, Harris TB, 
Hattersley AT, Heliovaara M, Hicks AA, Hingorani AD, Hoffmann W, Hofman A, 
Homuth G, Humphries SE, Hypponen E, Illig T, Jarvelin MR, Johansen B, Jousilahti 
P, Jula AM, Kaprio J, Kee F, Keinanen-Kiukaanniemi SM, Kooner JS, Kooperberg C, 
Kovacs P, Kraja AT, Kumari M, Kuulasmaa K, Kuusisto J, Lakka TA, Langenberg C, 
Le Marchand L, Lehtimaki T, Lyssenko V, Mannisto S, Marette A, Matise TC, 
McKenzie CA, McKnight B, Musk AW, Mohlenkamp S, Morris AD, Nelis M, 
Ohlsson C, Oldehinkel AJ, Ong KK, Palmer LJ, Penninx BW, Peters A, Pramstaller 
PP, Raitakari OT, Rankinen T, Rao DC, Rice TK, Ridker PM, Ritchie MD, Rudan I, 
Salomaa V, Samani NJ, Saramies J, Sarzynski MA, Schwarz PE, Shuldiner AR, 
Staessen JA, Steinthorsdottir V, Stolk RP, Strauch K, Tonjes A, Tremblay A, Tremoli 
E, Vohl MC, Volker U, Vollenweider P, Wilson JF, Witteman JC, Adair LS, Bochud 
M, Boehm BO, Bornstein SR, Bouchard C, Cauchi S, Caulfield MJ, Chambers JC, 
Chasman DI, Cooper RS, Dedoussis G, Ferrucci L, Froguel P, Grabe HJ, Hamsten A, 
Hui J, Hveem K, Jockel KH, Kivimaki M, Kuh D, Laakso M, Liu Y, Marz W, 
Munroe PB, Njolstad I, Oostra BA, Palmer CN, Pedersen NL, Perola M, Perusse L, 
Peters U, Power C, Quertermous T, Rauramaa R, Rivadeneira F, Saaristo TE, 
Saleheen D, Sinisalo J, Slagboom PE, Snieder H, Spector TD, Stefansson K, Stumvoll 
M, Tuomilehto J, Uitterlinden AG, Uusitupa M, van der Harst P, Veronesi G, Walker 
M, Wareham NJ, Watkins H, Wichmann HE, Abecasis GR, Assimes TL, Berndt SI, 
Boehnke M, Borecki IB, Deloukas P, Franke L, Frayling TM, Groop LC, Hunter DJ, 
Kaplan RC, O'Connell JR, Qi L, Schlessinger D, Strachan DP, Thorsteinsdottir U, van 
Duijn CM, Willer CJ, Visscher PM, Yang J, Hirschhorn JN, Zillikens MC, McCarthy 
MI, Speliotes EK, North KE, Fox CS, Barroso I, Franks PW, Ingelsson E, Heid IM, 
Loos RJ, Cupples LA, Morris AP, Lindgren CM, Mohlke KL: New genetic loci link 
adipose and insulin biology to body fat distribution. Nature 2015;518:187-196 
37. Ley CJ, Lees B, Stevenson JC: Sex- and menopause-associated changes in body-
fat distribution. The American journal of clinical nutrition 1992;55:950-954 
38. Svendsen OL, Hassager C, Christiansen C: Age- and menopause-associated 
variations in body composition and fat distribution in healthy women as measured by 
dual-energy X-ray absorptiometry. Metabolism 1995;44:369-373 
39. Preiss D, Sattar N: Non-alcoholic fatty liver disease: an overview of prevalence, 
diagnosis, pathogenesis and treatment considerations. Clin Sci (Lond) 2008;115:141-
150 
40. Grant BF, Dawson DA, Stinson FS, Chou SP, Dufour MC, Pickering RP: The 12-
month prevalence and trends in DSM-IV alcohol abuse and dependence: United 
States, 1991-1992 and 2001-2002. Drug Alcohol Depend 2004;74:223-234 
41. Holmila M, Raitasalo K: Gender differences in drinking: why do they still exist? 
Addiction 2005;100:1763-1769 
42. Scott RA, Lagou V, Welch RP, Wheeler E, Montasser ME, Luan J, Magi R, 
Strawbridge RJ, Rehnberg E, Gustafsson S, Kanoni S, Rasmussen-Torvik LJ, Yengo 
L, Lecoeur C, Shungin D, Sanna S, Sidore C, Johnson PC, Jukema JW, Johnson T, 
Mahajan A, Verweij N, Thorleifsson G, Hottenga JJ, Shah S, Smith AV, Sennblad B, 
Gieger C, Salo P, Perola M, Timpson NJ, Evans DM, Pourcain BS, Wu Y, Andrews 
Page 43 of 96
Diabetes
 JS, Hui J, Bielak LF, Zhao W, Horikoshi M, Navarro P, Isaacs A, O'Connell JR, 
Stirrups K, Vitart V, Hayward C, Esko T, Mihailov E, Fraser RM, Fall T, Voight BF, 
Raychaudhuri S, Chen H, Lindgren CM, Morris AP, Rayner NW, Robertson N, Rybin 
D, Liu CT, Beckmann JS, Willems SM, Chines PS, Jackson AU, Kang HM, 
Stringham HM, Song K, Tanaka T, Peden JF, Goel A, Hicks AA, An P, Muller-
Nurasyid M, Franco-Cereceda A, Folkersen L, Marullo L, Jansen H, Oldehinkel AJ, 
Bruinenberg M, Pankow JS, North KE, Forouhi NG, Loos RJ, Edkins S, Varga TV, 
Hallmans G, Oksa H, Antonella M, Nagaraja R, Trompet S, Ford I, Bakker SJ, Kong 
A, Kumari M, Gigante B, Herder C, Munroe PB, Caulfield M, Antti J, Mangino M, 
Small K, Miljkovic I, Liu Y, Atalay M, Kiess W, James AL, Rivadeneira F, 
Uitterlinden AG, Palmer CN, Doney AS, Willemsen G, Smit JH, Campbell S, Polasek 
O, Bonnycastle LL, Hercberg S, Dimitriou M, Bolton JL, Fowkes GR, Kovacs P, 
Lindstrom J, Zemunik T, Bandinelli S, Wild SH, Basart HV, Rathmann W, Grallert 
H, Maerz W, Kleber ME, Boehm BO, Peters A, Pramstaller PP, Province MA, 
Borecki IB, Hastie ND, Rudan I, Campbell H, Watkins H, Farrall M, Stumvoll M, 
Ferrucci L, Waterworth DM, Bergman RN, Collins FS, Tuomilehto J, Watanabe RM, 
de Geus EJ, Penninx BW, Hofman A, Oostra BA, Psaty BM, Vollenweider P, Wilson 
JF, Wright AF, Hovingh GK, Metspalu A, Uusitupa M, Magnusson PK, Kyvik KO, 
Kaprio J, Price JF, Dedoussis GV, Deloukas P, Meneton P, Lind L, Boehnke M, 
Shuldiner AR, van Duijn CM, Morris AD, Toenjes A, Peyser PA, Beilby JP, Korner 
A, Kuusisto J, Laakso M, Bornstein SR, Schwarz PE, Lakka TA, Rauramaa R, Adair 
LS, Smith GD, Spector TD, Illig T, de Faire U, Hamsten A, Gudnason V, Kivimaki 
M, Hingorani A, Keinanen-Kiukaanniemi SM, Saaristo TE, Boomsma DI, Stefansson 
K, van der Harst P, Dupuis J, Pedersen NL, Sattar N, Harris TB, Cucca F, Ripatti S, 
Salomaa V, Mohlke KL, Balkau B, Froguel P, Pouta A, Jarvelin MR, Wareham NJ, 
Bouatia-Naji N, McCarthy MI, Franks PW, Meigs JB, Teslovich TM, Florez JC, 
Langenberg C, Ingelsson E, Prokopenko I, Barroso I: Large-scale association analyses 
identify new loci influencing glycemic traits and provide insight into the underlying 
biological pathways. Nature genetics 2012;44:991-1005 
43. Harder MN, Ribel-Madsen R, Justesen JM, Sparso T, Andersson EA, Grarup N, 
Jorgensen T, Linneberg A, Hansen T, Pedersen O: Type 2 diabetes risk alleles near 
BCAR1 and in ANK1 associate with decreased beta-cell function whereas risk alleles 
near ANKRD55 and GRB14 associate with decreased insulin sensitivity in the Danish 
Inter99 cohort. The Journal of clinical endocrinology and metabolism 2013;98:E801-
806 
44. Wang Y, Rimm EB, Stampfer MJ, Willett WC, Hu FB: Comparison of abdominal 
adiposity and overall obesity in predicting risk of type 2 diabetes among men. The 
American journal of clinical nutrition 2005;81:555-563 
45. Stefan N, Kantartzis K, Machann J, Schick F, Thamer C, Rittig K, Balletshofer B, 
Machicao F, Fritsche A, Haring HU: Identification and characterization of 
metabolically benign obesity in humans. Arch Intern Med 2008;168:1609-1616 
46. Gupta AK, Bray GA, Greenway FL, Martin CK, Johnson WD, Smith SR: 
Pioglitazone, but not metformin, reduces liver fat in Type-2 diabetes mellitus 
independent of weight changes. J Diabetes Complications 2010;24:289-296 
47. Smith SR, De Jonge L, Volaufova J, Li Y, Xie H, Bray GA: Effect of pioglitazone 
on body composition and energy expenditure: a randomized controlled trial. 
Metabolism 2005;54:24-32 
48. Satoh T, Kidoya H, Naito H, Yamamoto M, Takemura N, Nakagawa K, Yoshioka 
Y, Morii E, Takakura N, Takeuchi O, Akira S: Critical role of Trib1 in differentiation 
of tissue-resident M2-like macrophages. Nature 2013;495:524-528 
Page 44 of 96
Diabetes
 49. Sung HK, Doh KO, Son JE, Park JG, Bae Y, Choi S, Nelson SM, Cowling R, 
Nagy K, Michael IP, Koh GY, Adamson SL, Pawson T, Nagy A: Adipose vascular 
endothelial growth factor regulates metabolic homeostasis through angiogenesis. Cell 
metabolism 2013;17:61-72 
50. Tien ES, Davis JW, Vanden Heuvel JP: Identification of the CREB-binding 
protein/p300-interacting protein CITED2 as a peroxisome proliferator-activated 
receptor alpha coregulator. J Biol Chem 2004;279:24053-24063 
51. Wardhana DA, Ikeda K, Barinda AJ, Nugroho DB, Qurania KR, Yagi K, Miyata 
K, Oike Y, Hirata KI, Emoto N: Family with sequence similarity 13, member A 
modulates adipocyte insulin signaling and preserves systemic metabolic homeostasis. 
Proc Natl Acad Sci U S A 2018;115:1529-1534 
52. Small KS, Hedman AK, Grundberg E, Nica AC, Thorleifsson G, Kong A, 
Thorsteindottir U, Shin SY, Richards HB, Soranzo N, Ahmadi KR, Lindgren CM, 
Stefansson K, Dermitzakis ET, Deloukas P, Spector TD, McCarthy MI: Identification 
of an imprinted master trans regulator at the KLF14 locus related to multiple 
metabolic phenotypes. Nature genetics 2011;43:561-564 
53. Small KS, Todorcevic M, Civelek M, El-Sayed Moustafa JS, Wang X, Simon 
MM, Fernandez-Tajes J, Mahajan A, Horikoshi M, Hugill A, Glastonbury CA, Quaye 
L, Neville MJ, Sethi S, Yon M, Pan C, Che N, Vinuela A, Tsai PC, Nag A, Buil A, 
Thorleifsson G, Raghavan A, Ding Q, Morris AP, Bell JT, Thorsteinsdottir U, 
Stefansson K, Laakso M, Dahlman I, Arner P, Gloyn AL, Musunuru K, Lusis AJ, Cox 
RD, Karpe F, McCarthy MI: Regulatory variants at KLF14 influence type 2 diabetes 
risk via a female-specific effect on adipocyte size and body composition. Nature 
genetics 2018;50:572-580 
54. Yujiri T, Nawata R, Takahashi T, Sato Y, Tanizawa Y, Kitamura T, Oka Y: MEK 
kinase 1 interacts with focal adhesion kinase and regulates insulin receptor substrate-1 
expression. J Biol Chem 2003;278:3846-3851 
55. Steinberg GR, Kemp BE, Watt MJ: Adipocyte triglyceride lipase expression in 
human obesity. Am J Physiol Endocrinol Metab 2007;293:E958-964 
56. Fagerberg L, Hallstrom BM, Oksvold P, Kampf C, Djureinovic D, Odeberg J, 
Habuka M, Tahmasebpoor S, Danielsson A, Edlund K, Asplund A, Sjostedt E, 
Lundberg E, Szigyarto CA, Skogs M, Takanen JO, Berling H, Tegel H, Mulder J, 
Nilsson P, Schwenk JM, Lindskog C, Danielsson F, Mardinoglu A, Sivertsson A, von 
Feilitzen K, Forsberg M, Zwahlen M, Olsson I, Navani S, Huss M, Nielsen J, Ponten 
F, Uhlen M: Analysis of the human tissue-specific expression by genome-wide 
integration of transcriptomics and antibody-based proteomics. Mol Cell Proteomics 
2014;13:397-406 
57. Sun G, French CR, Martin GR, Younghusband B, Green RC, Xie YG, Mathews 
M, Barron JR, Fitzpatrick DG, Gulliver W, Zhang H: Comparison of multifrequency 
bioelectrical impedance analysis with dual-energy X-ray absorptiometry for 
assessment of percentage body fat in a large, healthy population. The American 
journal of clinical nutrition 2005;81:74-78 
58. Borga M, West J, Bell JD, Harvey NC, Romu T, Heymsfield SB, Dahlqvist 
Leinhard O: Advanced body composition assessment: from body mass index to body 
composition profiling. Journal of investigative medicine : the official publication of 
the American Federation for Clinical Research 2018;66:1-9 
59. Ntuk UE, Gill JM, Mackay DF, Sattar N, Pell JP: Ethnic-specific obesity cutoffs 
for diabetes risk: cross-sectional study of 490,288 UK biobank participants. Diabetes 
Care 2014;37:2500-2507 
Page 45 of 96
Diabetes
 60. Huang-Doran I, Sleigh A, Rochford JJ, O'Rahilly S, Savage DB: Lipodystrophy: 
metabolic insights from a rare disorder. J Endocrinol 2010;207:245-255 
61. Shulman GI: Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic 
disease. N Engl J Med 2014;371:1131-1141 
62. Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R: 
Reversal of type 2 diabetes: normalisation of beta cell function in association with 
decreased pancreas and liver triacylglycerol. Diabetologia 2011;54:2506-2514 
 
Page 46 of 96
Diabetes
 Figure 1-a
20
15
10
5
4.0%
3.5%
3.0%
2.5%
0.025
0.030
0.035
0.040
t2d[, 1]
t2d[, 2]
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
1         2         3         4         5         6         7         8         9        10
Type 2 diabetes case/control 
proportion
Distribution of “favourable adiposity” 
polygenic score
“Favourable adiposity” polygenic score centile 
Higher adiposity
Lower adiposity
Page 47 of 96
Diabetes
 Figure 1-b
20
15
10
5
11.5%
11.0%
10.5%
10.0%
9.5%
0.095
0.100
0.105
0.110
0.115
cad[, 1]
cad[, 2]
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
1         2         3         4         5         6         7         8         9        10
Heart disease case/control 
proportion
Distribution of “favourable adiposity” 
polygenic score
“Favourable adiposity” polygenic score centile 
Higher adiposity
Lower adiposity
Page 48 of 96
Diabetes
 !"#$%&'()*
+,
(-
(,
-
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
--.
-/.
-0.
-+.
('''''''''+'''''''''0'''''''''/'''''''''-'''''''''1'''''''''2'''''''''3'''''''''4''''''''(,
567&%8&9:";9'*<:&=*;98%;>'
7%;7;%8";9
?":8%"@$8";9';A'BA<C;$%<@>&'<D"7;:"86E'
7;>6#&9"*':*;%&
B!<C;$%<@>&'<D"7;:"86E'7;>6#&9"*':*;%&'*&98">&'
5"#F&%'<D"7;:"86
G;H&%'<D"7;:"86
Page 49 of 96
Diabetes
 Effect on body fat %
Effect on waist-hip-ratio (BMI adjusted)
More effect on 
waist circumference
More effect on 
hip circumference
Women
Men
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
0.05
0.10
0.15
0.20
0.25
−0.004
−0.002
0.000
0.002
0.004
m_bfp[, "beta"]
m_whr[, "beta"]
AEBP2−PDE3A
LYPLAL1
GRB14
PPARG
MAFF
FAM13A
IRS1
TRIB1
ANKRD55
CITED2
DNAH10
PEPD
KLF14
VEGFA−C6orf223
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
0.05
0.10
0.15
0.20
0.25
−0.004
−0.002
0.000
0.002
0.004
f_bfp[, "beta"]
f_whr[, "beta"]
AEBP2−PDE3A
LYPLAL1
GRB14
PPARG
MAFF
FAM13A
IRS1
TRIB1
ANKRD55
CITED2
DNAH10
PEPD
KLF14
VEGFA−C6orf223
Figure 2
Page 50 of 96
Diabetes
 Subcutaneous fat
All
UK Biobank
Chu et al
NEO
TUF
DIRECT
Women
UK Biobank
Chu et al
NEO
TUF
DIRECT
Men
UK Biobank
Chu et al
NEO
TUF
DIRECT
Visceral fat
All
UK Biobank
Chu et al
NEO
TUF
DIRECT
Women
UK Biobank
Chu et al
NEO
TUF
DIRECT
Men
UK Biobank
Chu et al
NEO
TUF
DIRECT
VATSAT ratio
All
UK Biobank
Chu et al
NEO
TUF
DIRECT
Women
UK Biobank
Chu et al
NEO
TUF
DIRECT
Men
UK Biobank
Chu et al
NEO
TUF
DIRECT
Liver fat
All
UK Biobank
NEO
TUF
DIRECT
Women
UK Biobank
NEO
TUF
DIRECT
Men
UK Biobank
NEO
TUF
DIRECT
Figure 3
Page 51 of 96
Diabetes
 Genome-wide and abdominal MRI-imaging data provides evidence that a 
genetically determined favourable adiposity phenotype is characterized by lower 
ectopic liver fat and lower risk of type 2 diabetes, heart disease and 
hypertension. 
Yingjie Ji*1, Andrianos M. Yiorkas*2,3, Francesca Frau*4, Dennis Mook-
Kanamori*5,6, Harald Staiger*7,8,9, E. Louise Thomas10, Naeimeh Atabaki-Pasdar11, 
Archie Campbell12, Jessica Tyrrell1, Samuel E. Jones1, Robin N. Beaumont1, Andrew 
R. Wood1, Marcus A. Tuke1, Katherine S. Ruth1, Anubha Mahajan13, Anna Murray1, 
Rachel M. Freathy1, Michael N. Weedon1, Andrew T. Hattersley14, Caroline 
Hayward15, Jürgen Machann7,8, Hans-Ulrich Häring7,8,16, Paul Franks11,17,18, Renée de 
Mutsert5, Ewan Pearson19, Norbert Stefan*7,8,16, Timothy M. Frayling*1, Karla V. 
Allebrandt*4, Jimmy D. Bell*10, Alexandra I. Blakemore*2,3, Hanieh Yaghootkar*#1 
* Contributed equally 
# Corresponding author 
1- Genetics of Complex Traits, University of Exeter Medical School, University of 
Exeter, RILD Level 3, Royal Devon & Exeter Hospital, Barrack Road, Exeter EX2 
5DW, UK 
2- Section of Investigative Medicine, Imperial College London, London W12 0NN, 
UK 
3- Department of Life Sciences, Brunel University London, Uxbridge UB8 3PH, UK 
4- Translational Medicine and Early Development, TMED Translational Informatics, 
Sanofi, Frankfurt am Main, Germany 
5- Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, 
the Netherlands 
6- Department of Public Health and Primary Care, Leiden University Medical Center, 
Leiden, the Netherlands 
7- Institute for Diabetes Research and Metabolic Diseases of the Helmholtz Center 
Munich at the University of Tübingen, Otfried Müller Strasse 10, 72076 Tübingen, 
Germany 
8- German Center for Diabetes Research (DZD), Otfried-Müller-Strasse 10, 72076 
Tübingen, Germany 
9- Institute of Pharmaceutical Sciences, Department of Pharmacy and Biochemistry, 
Eberhard Karls University Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, 
Germany 
10- Research Centre for Optimal Health, School of Life Sciences, University of 
Page 52 of 96
Diabetes
 Westminster, London, UK  
11- Department of Clinical Sciences, Genetic and Molecular Epidemiology Unit, 
Lund University, Skåne University Hospital Malmö, SE-21741, Malmö, Sweden. 
12- Generation Scotland, Centre for Genomic and Experimental Medicine, Institute of 
Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK 
13- Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK. 
14- Institute of Biomedical and Clinical Science, University of Exeter Medical 
School, Exeter EX2 5DW, UK 
15- Medical Research Council Human Genetics Unit, Institute of Genetics and 
Molecular Medicine, University of Edinburgh, Edinburgh, UK 
16- Department of Internal Medicine IV, Division of Endocrinology, Diabetology, 
Angiology, Nephrology and Clinical Chemistry, Eberhard Karls University Tübingen, 
Otfried-Müller-Strase 10, 72076 Tübingen, Germany 
17- Department of Public Health & Clinical Medicine, Umeå University, Umeå, 
Sweden. 
18- Department of Nutrition, Harvard School of Public Health, Boston, MA, USA. 
19- Division of Molecular and Clinical Medicine, University of Dundee, Ninewells 
Hospital, Dundee, UK 
 
Corresponding author: Hanieh Yaghootkar 
University of Exeter Medical School, RILD building Level 3, Royal Devon & Exeter 
Hospital, Barrack Road, Exeter, EX2 5DW 
E-mail: h.yaghootkar@exeter.ac.uk 
 
 
 
 
Page 53 of 96
Diabetes
 Supplementary Table 1. Summary characteristics of participating studies. N: total number of sample size. 
Variable 
Statistics 
Unit 
UK Biobank 
NEO 
Tübingen 
Family Study 
for Type-2 
Diabetes (TÜF) 
IMI-DIRECT 
EXTEND 
GenScotland 
Age 
N 
years 
451099 
5744 
2679 
3029 
7537 
19988 
mean [min to max] 
(sd) 
57.3 [39.7, 73.7] 
(8) 
56.0 [44, 66] (5.9) 
42.8 [18, 82] 
(14.2) 
61.7 [30, 75] 
(6.9) 
56.3[18,98] 
(15.21) 
47.4[18,99] 
(14.98) 
Sex 
males / females 
NA 
206,251 / 244,848 
2,757 / 2,987 
970 / 1709 
2,142 / 887 
3,140 / 4,397 
8,220 / 11,774 
Body fat % 
N 
% 
443,000 
5,714 
2,553 
NA 
6,958 
19,438 
mean [min to max] 
(sd) 
31.4 [5, 69.8]  
(8.5) 
35.8[9.3,67.5]  
(8.9) 
34.2 [0.9, 74.9] 
(13.0) 
32 [1.2,59] 
(8.71) 
30 [1,62]  
(9.63) 
BMI (kg m-2) 
N 
kg/m2 
449359 
5744 
2679 
2871 
7498 
19781 
mean [min to max] 
(sd) 
27.4  [12.1, 74.7] 
(4.8) 
30.0 [17.2, 61.2] 
(4.8) 
31.0 [16.3, 86.5] 
(9.4) 
28.7 [16.9, 50.4] 
(4.4) 
27.2[14.3,48.6] 
(4.97) 
26.6[10.49,47.69] 
(5.00) 
WHR 
N 
NA 
450232 
5739 
2645 
2979 
7509 
19630 
mean [min to max] 
(sd) 
0.87 [0.2, 3]  
(0.09) 
0.92 [0.59, 1.25] 
(0.08) 
0.88 [0.41, 1.38] 
(0.10) 
0.97 [0.72, 1.26] 
(0.08) 
0.87[0.578,1.27]
(0.10) 
0.86[0.51,1.23] 
(0.09) 
Hip 
circumference 
N 
cm 
450276 
5739 
2645 
2979 
7476 
19586 
mean [min to max] 
(sd) 
103.4 [30, 195] 
(9.2) 
110 [74, 177]  
(10) 
111 [65, 201] 
(18) 
104.1 [84, 153] 
(8.7) 
104[65.4,144] 
(9.46) 
103.3[62,145] 
(9.95) 
Waist 
circumference 
N 
cm 
450323 
5739 
2648 
2985 
7512 
19651 
mean [min to max] 
(sd) 
90.3 [20, 197] 
(13.5) 
102 [57, 165]  
(13) 
98 [48, 185] 
(20) 
101 [65, 146] 
(11.8) 
90.3[54,150] 
(14.57) 
89.15[45,145] 
(13.85) 
Adiponectin 
N 
mg/L 
NA 
5718 
1270 
NA 
NA 
NA 
mean [min to max] 
(sd) 
8.4 [0.5, 41.8] 
(4.4) 
13.9 [0.4, 56.0] 
(7.4) 
Alanine 
transaminase 
N 
U/L 
NA 
5731 
1815 
NA 
5943 
NA 
mean [min to max] 
(sd) 
28.3 [4.7, 229.0] 
(14.7) 
29.6 [3.0, 161.0] 
(17.0) 
22.3[3.9,110] 
(11.08) 
Fasting insulin 
N 
mU/L 
NA 
5731 
2665 
2834 
NA 
NA 
mean [min to max] 
(sd) 
12.8 [0.05, 299.0] 
(11.0) 
14.6 [1.3, 137.2] 
(11.8) 
33.42[1.1,471.8] 
(53.9) 
HDL-C 
N 
mmol/
NA 
5727 
2584 
2869 
5932 
19157 
Page 55 of 96
Diabetes
 mean [min to max] 
(sd) 
L 
1.43 [0.24, 4.26] 
(0.41) 
1.61 [0.72, 4.14] 
(0.43) 
1.28 [0.1, 3.45] 
(0.37) 
1.72[0.62,4.43] 
(0.49) 
1.46[0.4,3.1] 
(0.40) 
Triglycerides 
N 
mmol/
L 
NA 
5727 
2601 
2869 
4906 
NA 
mean [min to max] 
(sd) 
1.46 [0.16, 20.40] 
(0.96) 
1.23[0.15,32.02]  
(1.11) 
1.42 [0.14, 6.52] 
(0.7) 
1.17[0.27,6.99] 
(0.65) 
Subcutaneous 
adipose tissue 
N 
 
5045 
2236 (cm2) 
833 (Kg) 
1320 (Kg) 
NA 
NA 
mean [min to max] 
(sd) 
litres 
7.03 [0.65-23.48] 
(3.20) 
300 [21, 783] 
(113) 
11.3 [0.0, 44.0] 
(6.1) 
6.64 [0.9, 21.9] 
(3.10) 
Visceral 
adipose tissue 
N 
 
5045 
2236 (cm2) 
906 (Kg) 
1323 (Kg) 
NA 
NA 
mean [min to max] 
(sd) 
litres 
3.74 [0.12-14.41] 
(2.25) 
123 [7, 426]  
(67) 
3.51[0.22,12.75] 
 (2.16) 
5.49 [0.2, 14.5] 
(2.35) 
VATSAT ratio 
N 
 
5045 
2236 
833 
1320 
NA 
NA 
mean [min to max] 
(sd) 
ratio 
0.57 [0.07-2.39] 
(0.34) 
0.45 [0.05, 5.92] 
(0.30) 
0.35 [0.00, 1.70] 
(0.25) 
0.94 [0.06, 3.21] 
(0.47) 
Liver fat 
N 
 
5045 
1821 
911 
1433 
NA 
NA 
mean [min to max] 
(sd) 
% 
4.13 [0.45-34.5] 
(4.6) 
8.85 [0.2, 62.9] 
(10.0) 
6.55[0.09,43.14] 
(6.87) 
6.19 [0.3, 37.6] 
(5.8) 
Pancreatic fat 
N 
 
NA 
NA 
NA 
1359 
NA 
NA 
mean [min to max] 
(sd) 
 
12.55 [0.2, 37.9] 
(8.6) 
Type 2 
diabetes 
N cases / N controls 
NA 
14,371 / 428,017 
580 / 5132 
0 / 2679 
795 / 2234 
1424 / 6113 
597 / 18985 
Systolic blood 
pressure 
(mmHg) 
N 
mmHg 
450075 
5735 
2041 
2736 
7532 
19929 
mean [min to max] 
(sd) 
144.2 [72, 252.5] 
(24) 
133 [85, 222]  
(17) 
133 [82, 218] 
(18) 
131.1 [90.1,199] 
(15.4) 
134[78,219] 
(20.34) 
132.8[74,209] 
(19.02) 
Diastolic blood 
pressure 
(mmHg) 
N 
mmHg 
449322 
5736 
2039 
2736 
7532 
19944 
mean [min to max] 
(sd) 
86.4 [36.5, 147] 
(13.5) 
85 [45, 145]  
(10) 
83 [40, 140] 
(12) 
79.6 [52, 117] 
(9.3) 
77.9[47,121] 
(10.96) 
80.61[42,124] 
(11.03) 
Hypertension 
N cases / N controls 
NA 
241,691 / 206,525 
392 / 5330 
NA 
1385 / 1416 
1767 / 5770 
2640 / 16942 
Heart disease 
N cases / N controls 
NA 
37,741 / 318,892 
2339 / 3997 
NA 
675 / 2349 
498 / 7039 
713 / 18869 
 
Page 56 of 96
Diabetes
 Supplementary Table 2. Fourthin variants associated with "favorable adiposity". The imputation information is for the UK Biobank study. 
BETA, SE and P-value are reported for the GWAS of body fat % in UK Biobank. SE: standard error; HWE: Hardy–Weinberg equilibrium. 
RSID 
Chr_pos 
Effect 
allele 
Other 
allele 
BETA 
(SD) 
SE 
p-value 
HWE  
p-value 
Imputation 
info 
MetaCCA 
p-value 
Gene context 
Association with other traits/diseases 
rs11118306 
1:219627486 
A 
G 
0.0202 
0.0015 
2E-40 
0.38 
0.99 
3.16E-21 
LYPLAL1---[]---
SLC30A10 
WHR, Insulin sensitivity, Fasting insulin, 
rs13389219 
2:165528876 
T 
C 
0.0169 
0.0015 
2E-29 
0.75 
0.99 
5.01E-41 
GRB14--[]--
COBLL1 
Triglycerides, Fasting insulin, WHR, 
Insulin sensitivity 
rs2943653 
2:227047771 
C 
T 
0.0158 
0.0016 
7E-24 
0.65 
0.99 
1.58E-43 
NYAP2---[]---
IRS1 
HDL-C, Fasting insulin, Insulin sensitivity 
rs1801282 
3:12393125 
G 
C 
0.0289 
0.0023 
3E-37 
0.09 
1 
2E-10 
[PPARG] 
Insulin sensitivity, Fasting insulin 
rs2276936 
4:89726283 
A 
C 
0.0122 
0.0015 
1E-16 
0.72 
0.99 
2.51E-20 
[FAM13A] 
WHR, Insulin sensitivity, Fasting insulin, 
rs40271 
5:55796319 
C 
T 
0.0116 
0.0017 
6E-12 
0.03 
0.99 
1E-12 
ANKRD55---[]---
MAP3K1 
Insulin sensitivity, Fasting insulin 
rs632057 
6:139834012 
G 
T 
0.0087 
0.0015 
2E-8 
0.62 
1 
3.16E-10 
CITED2---[] 
 
rs998584 
6:43757896 
C 
A 
0.009 
0.0015 
3E-9 
0.74 
0.99 
5E-11 
VEGFA-[]---
C6orf223 
WHR 
rs972283 
7:130466854 
A 
G 
0.0143 
0.0015 
5E-22 
0.68 
1 
1.26E-19 
KLF14--[]---
MKLN1 
HDL-C, Insulin sensitivity 
rs2980888 
8:126507308 
C 
T 
0.0119 
0.0016 
9E-14 
0.39 
0.99 
1.26E-35 
TRIB1--[] 
Adiponectin, ALT, HDL-C, Triglycerides, 
Insulin sensitivity 
rs7133378 
12:124409502 
A 
G 
0.019 
0.0016 
2E-33 
0.63 
0.99 
2E-17 
[DNAH10] 
Adiponectin, HDL-C, WHR, Insulin 
sensitivity 
rs11045172 
12:20470221 
C 
A 
0.0108 
0.0019 
8E-9 
0.32 
0.99 
3.98E-9 
AEBP2---[]--
PDE3A 
Adiponectin 
rs7258937 
19:33938800 
T 
C 
0.0157 
0.0015 
5E-26 
0.52 
0.99 
5E-12 
[PEPD] 
Insulin sensitivity, Fasting insulin 
rs2267373 
22:38600542 
C 
T 
0.0169 
0.0015 
4E-29 
0.56 
0.99 
7.94E-14 
[MAFF] 
 
 
Page 57 of 96
Diabetes
 Supplementary Table 3. Genetic variants associated with body fat % (GWAS in UK Biobank individuals) and a multivariate GWAS of 7 
metabolic biomarkers (from published GWASs). SE: standard error; HWE: Hardy–Weinberg equilibrium. 
RSID  
Chr_pos 
Effect 
allele 
Other 
allele 
BETA 
SE 
p-value 
HWE 
p-value 
Imputation 
info 
MetaCCA 
p-value 
Gene context 
r2_UKB 
Lead SNP from UKB 
rs2943653 
2:227047771 
C 
T 
0.0158 
0.0016 
7E-24 
0.65 
0.99 
1.58E-43 
NYAP2---[]---
IRS1 
1 
LEAD 
rs13389219 
2:165528876 
T 
C 
0.0169 
0.0015 
2E-29 
0.75 
0.99 
5.01E-41 
GRB14--[]--
COBLL1 
1 
LEAD 
rs2980888 
8:126507308 
C 
T 
0.0119 
0.0016 
9E-14 
0.39 
0.99 
1.26E-35 
TRIB1--[] 
0.68 
rs183929111 
rs11118306 
1:219627486 
A 
G 
0.0202 
0.0015 
2E-40 
0.38 
0.99 
3.16E-21 
LYPLAL1---[]---
SLC30A10 
0.99 
1:219665643_ACTGGTGTTA 
GAATT_A 
rs2276936 
4:89726283 
A 
C 
0.0122 
0.0015 
1E-16 
0.72 
0.99 
2.51E-20 
[FAM13A] 
0.92 
rs548008292 
rs972283 
7:130466854 
A 
G 
0.0143 
0.0015 
5E-22 
0.68 
1 
1.26E-19 
KLF14--[]---
MKLN1 
1 
LEAD 
rs7133378 
12:124409502 
A 
G 
0.019 
0.0016 
2E-33 
0.63 
0.99 
2.00E-17 
[DNAH10] 
1 
LEAD 
rs2267373 
22:38600542 
C 
T 
0.0169 
0.0015 
4E-29 
0.56 
0.99 
7.94E-14 
[MAFF] 
0.99 
rs4820325 
rs40271 
5:55796319 
C 
T 
0.0116 
0.0017 
6E-12 
0.03 
0.99 
1.00E-12 
ANKRD55---[]---
MAP3K1 
0.99 
rs30351 
rs7258937 
19:33938800 
T 
C 
0.0157 
0.0015 
5E-26 
0.52 
0.99 
5.01E-12 
[PEPD] 
1 
LEAD 
rs998584 
6:43757896 
C 
A 
0.009 
0.0015 
3E-9 
0.74 
0.99 
5.01E-11 
VEGFA-[]---
C6orf223 
1 
LEAD 
rs1801282 
3:12393125 
G 
C 
0.0289 
0.0023 
3E-37 
0.09 
1 
2.00E-10 
[PPARG] 
1 
LEAD 
rs632057 
6:139834012 
G 
T 
0.0087 
0.0015 
2E-8 
0.62 
1 
3.16E-10 
CITED2---[] 
0.92 
rs143770783 
rs11045172 
12:20470221 
C 
A 
0.0108 
0.0019 
8E-9 
0.32 
0.99 
3.98E-09 
AEBP2---[]--
PDE3A 
1 
LEAD 
rs12940684 
17:7453919 
C 
T 
0.0111 
0.0016 
2E-11 
0.56 
0.99 
1.26E-43 
[TNFSF12-
TNFSF13] 
1 
LEAD 
rs1558902 
16:53803574 
A 
T 
0.0413 
0.0015 
4E-164 
0.48 
0.99 
1.26E-19 
[FTO] 
0.99 
PROXY 
rs4497915 
2:48690596 
G 
T 
0.0081 
0.0015 
3E-8 
0.52 
0.99 
3.16E-19 
[PPP1R21] 
1 
LEAD 
Page 58 of 96
Diabetes
 rs6024001 
20:36842836 
C 
T 
0.0086 
0.0015 
4E-9 
0.75 
0.99 
1.58E-17 
[KIAA1755] 
0.94 
PROXY 
rs10496731 
2:135597628 
T 
G 
0.0097 
0.0015 
4E-10 
0.11 
0.99 
2.51E-12 
[ACMSD] 
1 
LEAD 
rs7239114 
18:45921214 
A 
G 
0.009 
0.0015 
3E-9 
0.59 
0.99 
6.31E-12 
ZBTB7C---[]---
CTIF 
1 
LEAD 
rs340025 
15:60908307 
C 
T 
0.0089 
0.0015 
2E-9 
0.93 
0.99 
3.98E-11 
[RORA] 
1 
LEAD 
rs17207196 
7:75101065 
C 
T 
0.0131 
0.0015 
2E-18 
0.51 
1 
2.51E-10 
[POM121C] 
0.99 
PROXY 
rs7903146 
10:114758349 
C 
T 
0.0109 
0.0016 
3E-11 
0.5 
1 
2.51E-10 
[TCF7L2] 
0.89 
PROXY 
rs9435341 
1:107616641 
T 
C 
0.0105 
0.0016 
2E-11 
0.0004 
0.99 
2.51E-10 
PRMT6--[]--
NTNG1 
1 
LEAD 
rs10779835 
1:230299949 
T 
C 
0.0093 
0.0015 
3E-10 
0.77 
0.99 
5.01E-10 
[GALNT2] 
0.99 
PROXY 
rs8074454 
17:3981148 
C 
G 
0.0105 
0.0016 
3E-11 
0.59 
0.99 
5.01E-10 
[ZZEF1] 
1 
LEAD 
rs9538162 
13:59265043 
T 
C 
0.0087 
0.0015 
6E-9 
0.36 
0.99 
7.94E-10 
PCDH17---[]---
DIAPH3 
0.98 
PROXY 
rs11096549 
2:16607101 
T 
C 
0.0095 
0.0017 
8E-9 
0.32 
0.99 
7.94E-09 
MYCN---[]---
FAM49A 
1 
LEAD 
rs7621025 
3:136272246 
C 
T 
0.0091 
0.0017 
3E-8 
0.65 
0.99 
2.51E-08 
[STAG1] 
0.98 
PROXY 
rs6752378 
2:25150116 
A 
C 
0.023 
0.0015 
3E-55 
0.09 
0.99 
2.51E-08 
ADCY3-[]--
DNAJC27 
1 
LEAD 
rs2298117 
10:70346740 
T 
C 
0.0098 
0.0015 
3E-10 
0.46 
0.99 
2.51E-08 
[TET1] 
0.92 
PROXY 
rs79011 
22:41866938 
A 
G 
0.0144 
0.0019 
1E-14 
0.28 
0.99 
3.16E-08 
[ACO2] 
0.99 
PROXY 
rs7124681 
11:47529947 
A 
C 
0.0225 
0.0015 
4E-50 
0.14 
1 
3.98E-08 
CELF1--[]--
PTPMT1 
1 
LEAD 
 
 
 
Page 59 of 96
Diabetes
 Supplementary Table 4. The association of genetic variants with 6 metabolic biomarkers. A1: effect allele; A0: other allele; P: p-value; Adipo: 
adiponectin; ALT: alanine transaminase; HDL: HDL-cholesterol; SHBG: Sex-hormone binding globulin; TG: triglycerides; FIadjBMI: fasting 
insulin adjusted for BMI. 
RSID 
Chr:Position 
GENE 
CONTEXT 
A
1 
A
0 
Beta 
Adipo 
P 
Adip
o 
Beta 
ALT 
P 
ALT 
Beta 
HDL 
P 
HDL 
Beta 
SHB
G 
P 
SHBG 
Beta 
TG 
P 
TG 
Beta 
FIadjBM
I 
P 
FIadjBM
I 
rs1294068
4 
17:7453919 
[TNFSF12-TNFSF13] 
C 
T 
0.007 
0.17 
0.0031 
0.172 
0.006
8 
0.2 
0.079 
3E-56 
-8E-4 
0.5009 
-7E-4 
0.8 
rs2943653 
2:227047771 
NYAP2---[]---IRS1 
C 
T 
0.022 
4E-6 
-
0.0034 
0.033 
0.031
2 
5E-9 
0.014 
0.005 
-0.026 
8E-8 
-0.021 
5E-14 
rs1338921
9 
2:165528876 
GRB14--[]--COBLL1 
T 
C 
0.019 
3E-5 
-
0.0041 
0.001 
0.025
4 
2E-7 
0.016 
4E-4 
-0.029 
3E-10 
-0.018 
7E-11 
rs2980888 
8:126507308 
TRIB1--[] 
C 
T 
0.033 
4E-8 
-
0.0104 
5E-9 
0.040
7 
8E-12 
0.003 
0.5 
-0.067 
2E-31 
-0.0019 
0.55 
rs1111830
6 
1:219627486 
LYPLAL1---[]---
SLC30A10 
A 
G 
0.019 
4E-5 
-
0.0031 
0.113 
0.020
3 
0.0004 
0.006 
0.18 
-0.016 
0.002 
-0.014 
5E-7 
rs2276936 
4:89726283 
[FAM13A] 
A 
C 
0.020 
8E-6 
-
0.0018 
0.084 
0.021
9 
1E-5 
7E-4 
0.86 
-0.013 
0.024 
-0.012 
2E-5 
rs972283 
7:130466854 
KLF14--[]---MKLN1 
A 
G 
-0.006 
0.2 
-9E-4 
0.31 
0.037
7 
6E-15 
0.004 
0.36 
-0.021 
1E-5 
-0.013 
4E-6 
rs1558902 
16:53803574 
[FTO] 
A 
T 
0.0033 
0.47 
0.0029 
0.045 
-0.021 
5E-6 
0.007 
0.1 
0.014 
0.008 
-0.003 
0.22 
rs4497915 
2:48690596 
[PPP1R21] 
G 
T 
0.0058 
0.2 
0.0049 
0.0001 
-0.01 
0.054 
0.015 
4E-4 
0.007 
0.115 
-0.005 
0.08 
rs6024001 
20:36842836 
[KIAA1755] 
C 
T 
-0.009 
0.04 
0.0048 
0.0003 
-0.013 
0.002 
-5E-4 
0.9 
0.004 
0.378 
0.0072 
0.0066 
rs7133378 
12:12440950
2 
[DNAH10] 
A 
G 
0.0297 
1E-9 
-4E-4 
0.83 
0.031 
4E-9 
0.008 
0.1 
-0.023 
6E-6 
-0.008 
0.009 
rs7958691 
12:12444074
3 
[CCDC92] 
T 
G 
0.0268 
1E-8 
0.0016 
0.59 
0.032 
6E-10 
0.007 
0.15 
-0.027 
9E-8 
-0.007 
0.01 
rs2267373 
22:38600542 
[MAFF] 
C 
T 
-
0.0004 
0.9 
-
0.0039 
0.07 
0.015 
0.003 
-0.005 
0.23 
-0.024 
5E-7 
-0.008 
0.004 
Page 60 of 96
Diabetes
 rs40271 
5:55796319 
ANKRD55---[]---
MAP3K1 
C 
T 
-
0.0059 
0.26 
-0.003 
0.02 
0.02 
0.0003 
0.018 
5E-4 
-0.023 
4E-5 
-0.012 
5E-5 
rs1049673
1 
2:135597628 
[ACMSD] 
T 
G 
0.0059 
0.22 
0.0051 
0.007 
-0.02 
0.006 
-0.002 
0.65 
0.006 
0.26 
0.0052 
0.067 
rs7258937 
19:33938800 
[PEPD] 
T 
C 
0.0188 
2E-5 
8E-4 
0.95 
0.016 
0.001 
0.006 
0.19 
-0.009 
0.097 
-0.008 
0.002 
rs7239114 
18:45921214 
ZBTB7C---[]---CTIF 
A 
G 
-
0.0065 
0.2 
0.0053 
0.002 
-0.014 
0.02 
-0.005 
0.34 
0.005 
0.278 
-0.005 
0.12 
rs340025 
15:60908307 
[RORA] 
C 
T 
0.0023 
0.6 
0.005 
0.001 
0.004
5 
0.42 
0.001 
0.82 
3E-4 
0.864 
-0.001 
0.7 
rs998584 
6:43757896 
VEGFA-[]---
C6orf223 
C 
A 
0.0296 
6E-8 
0.0025 
0.58 
0.024 
2E-5 
0.012 
0.02 
-0.03 
4E-7 
-0.006 
0.04 
rs1801282 
3:12393125 
[PPARG] 
G 
C 
0.0034 
0.6 
-0.005 
0.21 
0.021 
0.004 
0.018 
0.003 
-0.02 
0.0027 
-0.022 
8E-9 
rs1720719
6 
7:75101065 
[POM121C] 
C 
T 
-
0.0009 
0.87 
0.0037 
0.29 
-0.009 
0.077 
0.007 
0.1 
0.0096 
0.189 
0.011 
0.0002 
rs7903146 
10:11475834
9 
[TCF7L2] 
C 
T 
-
0.0022 
0.66 
-0.001 
0.51 
0.003
3 
0.78 
0.004 
0.4 
-0.01 
0.038 
0.014 
5E-6 
rs9435341 
1:107616641 
PRMT6--[]--NTNG1 
T 
C 
0.0106 
0.026 
0.0018 
0.34 
-0.009 
0.04 
0.025 
3E-8 
0.005 
0.286 
0.006 
0.027 
rs632057 
6:139834012 
CITED2---[] 
G 
T 
0.0203 
1E-5 
-
0.0014 
0.25 
0.024 
5E-7 
0.001 
0.77 
-0.023 
9E-6 
-0.006 
0.026 
rs1077983
5 
1:230299949 
[GALNT2] 
T 
C 
0.0078 
0.085 
0.0011 
0.65 
-0.043 
6E-20 
4E-4 
0.9 
0.036 
1E-13 
-9E-4 
0.748 
rs8074454 
17:3981148 
[ZZEF1] 
C 
G 
-
0.0058 
0.23 
-
0.0052 
0.006 
-0.009 
0.07 
0.005 
0.3 
6E-4 
0.97 
-0.0016 
0.57 
rs9538162 
13:59265043 
PCDH17---[]---
DIAPH3 
T 
C 
0.001 
0.82 
-
0.0047 
0.031 
0.009 
0.14 
0.005 
0.2 
-
0.0045 
0.24 
-0.0025 
0.36 
rs1104517
2 
12:20470221 
AEBP2---[]--PDE3A 
C 
A 
0.0365 
5E-8 
-0.007 
0.007 
0.029 
3E-6 
0.007 
0.3 
-0.019 
0.0033 
-0.003 
0.39 
rs1109654
9 
2:16607101 
MYCN---[]---
FAM49A 
T 
C 
0.0017 
0.7 
-0.002 
0.2 
-0.006 
0.19 
0.012 
0.01 
0.006 
0.2 
0.011 
0.0002 
rs7621025 
3:136272246 
[STAG1] 
C 
T 
-
0.0035 
0.49 
0.0065 
0.0003 
-0.026 
4E-6 
-0.023 
1E-5 
0.026 
1E-6 
0.0044 
0.16 
rs6752378 
2:25150116 
ADCY3-[]--
DNAJC27 
A 
C 
0.0082 
0.07 
0.0027 
0.6 
-0.011 
0.03 
0.006 
0.17 
0.002 
0.89 
-0.0037 
0.16 
rs2298117 
10:70346740 
[TET1] 
T 
C 
-
0.0043 
0.35 
-
0.0012 
0.49 
-0.008 
0.11 
-0.009 
0.04 
0.01 
0.027 
0.01 
0.0002 
Page 61 of 96
Diabetes
 rs79011 
22:41866938 
[ACO2] 
A 
G 
0.0085 
0.12 
0.0057 
0.001 
0.002 
0.89 
0.009 
0.08 
7E-4 
0.83 
-0.0025 
0.44 
 
 
Supplementary Table 5. The association of "favourable adiposity" polygenic score with measures of adiposity and biomarkers from 
independent studies. The effects are in SD. P: p-value; N: total sample size; Adipo: adiponectin; ALT: alanine transaminase; BF%: body fat 
percentage; HDL: HDL-cholesterol; TG: triglycerides. 
 
 
NEO 
EXTEND 
GenScotland 
TUF 
DIRECT 
Meta-analysis 
 
Trait 
Beta 
P 
N 
Beta 
P 
N 
Beta 
P 
N 
Beta 
P 
N 
Beta 
P 
N 
Beta 
SE 
P 
N 
14 SNPs 
BF % 
0.014 
7E-4 
5714 
0.015 
0.002 
6792 
0.012 
2E-6 
19431 
0.034 
3E-5 
2483 
NA 
NA 
NA 
0.02 
0.002 
1E-13 
34420 
BMI 
0.012 
0.04 
5744 
0.007 
0.2 
7330 
0.001 
0.8 
19270 
0.04 
7E-6 
2604 
0.02 
0.001 
2705 
0.01 
0.002 
4E-4 
37653 
ALT 
-0.01 
0.12 
5731 
-0.011 
0.05 
5800 
NA 
NA 
NA 
-0.02 
0.09 
1755 
NA 
NA 
NA 
-0.01 
0.003 
0.003 
13286 
TG 
-0.03 
8E-8 
5727 
-0.03 
3E-5 
4803 
NA 
NA 
NA 
-0.02 
0.05 
2526 
NA 
NA 
NA 
-0.03 
0.004 
5E-12 
13056 
HDL 
0.03 
5E-8 
5727 
0.023 
2E-5 
5792 
0.022 
4E-17 
18770 
0.015 
7E-2 
2509 
NA 
NA 
NA 
0.02 
0.002 
6E-28 
32798 
Adipo 
0.03 
1E-10 
5718 
NA 
NA 
NA 
NA 
NA 
NA 
0.008 
0.5 
1240 
NA 
NA 
NA 
0.03 
0.005 
5E-10 
6958 
Fasting 
insulin 
-0.01 
0.01 
5731 
NA 
NA 
NA 
NA 
NA 
NA 
-0.01 
0.08 
2590 
NA 
NA 
NA 
-0.01 
0.004 
0.003 
8321 
7 
"additional" 
SNPs 
BF % 
0.01 
0.16 
5714 
0.007 
0.3 
6792 
0.008 
0.1 
19431 
0.02 
0.08 
2513 
NA 
NA 
NA 
0.01 
0.003 
0.005 
34450 
BMI 
0.01 
0.13 
5744 
0.001 
0.9 
7330 
-0.004 
0.4 
19270 
0.04 
0.002 
2639 
0.02 
0.041 
2705 
0.01 
0.003 
0.1 
37688 
Page 62 of 96
Diabetes
 ALT 
-
0.001 
0.87 
5731 
-0.02 
0.02 
5800 
NA 
NA 
NA 
-0.01 
0.6 
1784 
NA 
NA 
NA 
-0.01 
0.005 
0.06 
13315 
TG 
-0.04 
4E-6 
5727 
-0.04 
1E-6 
4803 
NA 
NA 
NA 
-0.03 
0.008 
2561 
NA 
NA 
NA 
-0.04 
0.005 
9E-13 
13091 
HDL 
0.03 
2E-4 
5727 
0.028 
2E-4 
5792 
0.027 
2E-8 
18770 
0.02 
0.06 
2544 
NA 
NA 
NA 
0.03 
0.003 
2E-15 
32833 
Adipo 
0.02 
8E-3 
5718 
NA 
NA 
NA 
NA 
NA 
NA 
0.004 
0.8 
1253 
NA 
NA 
NA 
0.02 
0.007 
0.01 
6971 
Fasting 
insulin 
0.001 
0.9 
5731 
NA 
NA 
NA 
NA 
NA 
NA 
-0.01 
0.5 
2625 
NA 
NA 
NA 
-0.003 
0.007 
0.6 
8356 
 
Supplementary Table 6. The association of "favourable adiposity" polygenic score and individual variants with body fat % and disease 
outcomes from published GWAS studies. SE: standard error; P: p-value. 
Outcome 
Analysis 
Exposure 
Effect 
SE 
P 
Reference 
Body fat % 
All 
14 SNPs 
0.16 % 
0.001 
1x10-43 
Lu et al, Nature communication, 2011 
Type 2 diabetes 
All 
14 SNPs 
0.96 OR 
0.004 
7x10-21 
Mahajan et al, Nature genetics, 2014 
Heart disease 
All 
14 SNPs 
0.98 OR 
0.003 
2x10-15 
Nikpey et al, Nature genetics, 2015 
Systolic blood pressure 
All 
14 SNPs 
-0.15 mmHg 
0.02 
3x10-15 
Wain et al, Hypertension, 2017 
Diastolic blood 
 
All 
14 SNPs 
-0.08 mmHg 
0.01 
3x10-12 
Wain et al, Hypertension, 2017 
Body fat % 
All 
7 "additional" SNPs 
0.14% 
0.002 
5x10-16 
Lu et al, Nature communication, 2011 
Type 2 diabetes 
All 
7 "additional" SNPs 
0.98 OR 
0.006 
2x10-4 
Mahajan et al, Nature genetics, 2014 
Heart disease 
All 
7 "additional" SNPs 
0.98 OR 
0.004 
3x10-8 
Nikpey et al, Nature genetics, 2015 
Systolic blood pressure 
All 
7 "additional" SNPs 
-0.14 mmHg 
0.02 
2x10-7 
Wain et al, Hypertension, 2017 
Diastolic blood 
 
All 
7 "additional" SNPs 
-0.08 mmHg 
0.02 
1.5x10-6 
Wain et al, Hypertension, 2017 
Type 2 diabetes 
All 
AEBP2---[]--PDE3A 
0.97 OR 
0.02 
0.2 
Mahajan et al, Nature genetics, 2014 
Type 2 diabetes 
All 
LYPLAL1---[]---SLC30A10 
0.97 OR 
0.02 
0.033 
Mahajan et al, Nature genetics, 2014 
Type 2 diabetes 
All 
GRB14--[]--COBLL1 
0.93 OR 
0.01 
8E-7 
Mahajan et al, Nature genetics, 2014 
Type 2 diabetes 
All 
[PPARG] 
0.88 OR 
0.02 
5.7E-10 
Mahajan et al, Nature genetics, 2014 
Type 2 diabetes 
All 
[MAFF] 
1 OR 
0.01 
0.76 
Mahajan et al, Nature genetics, 2014 
Type 2 diabetes 
All 
[FAM13A] 
0.98 OR 
0.01 
0.095 
Mahajan et al, Nature genetics, 2014 
Type 2 diabetes 
All 
NYAP2---[]---IRS1 
0.92 OR 
0.02 
0.000000024 
Mahajan et al, Nature genetics, 2014 
Page 63 of 96
Diabetes
 Type 2 diabetes 
All 
TRIB1--[] 
1.01 OR 
0.02 
0.62 
Mahajan et al, Nature genetics, 2014 
Type 2 diabetes 
All 
ANKRD55---[]---MAP3K1 
0.95 OR 
0.02 
0.00052 
Mahajan et al, Nature genetics, 2014 
Type 2 diabetes 
All 
CITED2---[] 
0.99 OR 
0.01 
0.42 
Mahajan et al, Nature genetics, 2014 
Type 2 diabetes 
All 
[DNAH10] 
0.95 OR 
0.02 
0.0073 
Mahajan et al, Nature genetics, 2014 
Type 2 diabetes 
All 
[PEPD] 
0.96 OR 
0.02 
0.0057 
Mahajan et al, Nature genetics, 2014 
Type 2 diabetes 
All 
KLF14--[]---MKLN1 
0.95 OR 
0.02 
0.00045 
Mahajan et al, Nature genetics, 2014 
Type 2 diabetes 
All 
VEGFA-[]---C6orf223 
0.97 OR 
0.02 
0.1 
Mahajan et al, Nature genetics, 2014 
Heart disease 
All 
AEBP2---[]--PDE3A 
1 OR 
0.01 
0.9766445 
Nikpey et al, Nature genetics, 2015 
Heart disease 
All 
LYPLAL1---[]---SLC30A10 
0.99 OR 
0.01 
0.306953 
Nikpey et al, Nature genetics, 2015 
Heart disease 
All 
GRB14--[]--COBLL1 
0.97 OR 
0.01 
0.0187829 
Nikpey et al, Nature genetics, 2015 
Heart disease 
All 
[PPARG] 
0.998 OR 
0.01 
0.9364154 
Nikpey et al, Nature genetics, 2015 
Heart disease 
All 
[MAFF] 
0.998 OR 
0.01 
0.85394 
Nikpey et al, Nature genetics, 2015 
Heart disease 
All 
[FAM13A] 
0.98 OR 
0.01 
0.0500724 
Nikpey et al, Nature genetics, 2015 
Heart disease 
All 
NYAP2---[]---IRS1 
0.96 OR 
0.01 
0.000053 
Nikpey et al, Nature genetics, 2015 
Heart disease 
All 
TRIB1--[] 
0.96 OR 
0.01 
0.0000666 
Nikpey et al, Nature genetics, 2015 
Heart disease 
All 
ANKRD55---[]---MAP3K1 
0.98 OR 
0.01 
0.0745602 
Nikpey et al, Nature genetics, 2015 
Heart disease 
All 
CITED2---[] 
0.99 OR 
0.01 
0.1972927 
Nikpey et al, Nature genetics, 2015 
Heart disease 
All 
[DNAH10] 
0.97 OR 
0.01 
0.0059085 
Nikpey et al, Nature genetics, 2015 
Heart disease 
All 
[PEPD] 
0.97 OR 
0.01 
0.0011167 
Nikpey et al, Nature genetics, 2015 
Heart disease 
All 
KLF14--[]---MKLN1 
0.98 OR 
0.01 
0.0282587 
Nikpey et al, Nature genetics, 2015 
Heart disease 
All 
VEGFA-[]---C6orf223 
0.96 OR 
0.01 
0.0000221 
Nikpey et al, Nature genetics, 2015 
Systolic blood pressure 
All 
AEBP2---[]--PDE3A 
-0.007 mmHg 
0.08 
0.92708814 
Wain et al, Hypertension, 2017 
Systolic blood pressure 
All 
LYPLAL1---[]---SLC30A10 
-0.193 mmHg 
0.07 
0.003606794 
Wain et al, Hypertension, 2017 
Systolic blood pressure 
All 
GRB14--[]--COBLL1 
-0.171 mmHg 
0.07 
0.008912066 
Wain et al, Hypertension, 2017 
Systolic blood pressure 
All 
[PPARG] 
0.017 mmHg 
0.09 
0.854389408 
Wain et al, Hypertension, 2017 
Systolic blood pressure 
All 
[MAFF] 
0.049 mmHg 
0.07 
0.454212446 
Wain et al, Hypertension, 2017 
Systolic blood pressure 
All 
[FAM13A] 
-0.132 mmHg 
0.06 
0.040574444 
Wain et al, Hypertension, 2017 
Systolic blood pressure 
All 
NYAP2---[]---IRS1 
-0.312 mmHg 
0.07 
3.96244E-06 
Wain et al, Hypertension, 2017 
Systolic blood pressure 
All 
TRIB1--[] 
-0.111 mmHg 
0.07 
0.129211778 
Wain et al, Hypertension, 2017 
Systolic blood pressure 
All 
ANKRD55---[]---MAP3K1 
-0.12 mmHg 
0.07 
0.103187472 
Wain et al, Hypertension, 2017 
Systolic blood pressure 
All 
CITED2---[] 
-0.22 mmHg 
0.07 
0.000981594 
Wain et al, Hypertension, 2017 
Systolic blood pressure 
All 
[DNAH10] 
-0.19 mmHg 
0.07 
0.007897604 
Wain et al, Hypertension, 2017 
Systolic blood pressure 
All 
[PEPD] 
-0.099 mmHg 
0.06 
0.118136956 
Wain et al, Hypertension, 2017 
Systolic blood pressure 
All 
KLF14--[]---MKLN1 
-0.253 mmHg 
0.07 
0.000108203 
Wain et al, Hypertension, 2017 
Systolic blood pressure 
All 
VEGFA-[]---C6orf223 
-0.201 mmHg 
0.07 
0.005721477 
Wain et al, Hypertension, 2017 
Diastolic blood 
 
All 
AEBP2---[]--PDE3A 
-0.053 mmHg 
0.05 
0.278393597 
Wain et al, Hypertension, 2017 
Page 64 of 96
Diabetes
 Diastolic blood 
 
All 
LYPLAL1---[]---SLC30A10 
-0.056 mmHg 
0.04 
0.173513933 
Wain et al, Hypertension, 2017 
Diastolic blood 
 
All 
GRB14--[]--COBLL1 
-0.096 mmHg 
0.04 
0.017430699 
Wain et al, Hypertension, 2017 
Diastolic blood 
 
All 
[PPARG] 
0.066 mmHg 
0.06 
0.257194407 
Wain et al, Hypertension, 2017 
Diastolic blood 
 
All 
[MAFF] 
0.025 mmHg 
0.04 
0.543799397 
Wain et al, Hypertension, 2017 
Diastolic blood 
 
All 
[FAM13A] 
-0.116 mmHg 
0.04 
0.003577279 
Wain et al, Hypertension, 2017 
Diastolic blood 
 
All 
NYAP2---[]---IRS1 
-0.148 mmHg 
0.04 
0.000360846 
Wain et al, Hypertension, 2017 
Diastolic blood 
 
All 
TRIB1--[] 
-0.061 mmHg 
0.04 
0.171755508 
Wain et al, Hypertension, 2017 
Diastolic blood 
 
All 
ANKRD55---[]---MAP3K1 
-0.046 mmHg 
0.05 
0.309485295 
Wain et al, Hypertension, 2017 
Diastolic blood 
 
All 
CITED2---[] 
-0.122 mmHg 
0.04 
0.002630972 
Wain et al, Hypertension, 2017 
Diastolic blood 
 
All 
[DNAH10] 
-0.096 mmHg 
0.04 
0.02527869 
Wain et al, Hypertension, 2017 
Diastolic blood 
 
All 
[PEPD] 
-0.091 mmHg 
0.04 
0.019628177 
Wain et al, Hypertension, 2017 
Diastolic blood 
 
All 
KLF14--[]---MKLN1 
-0.083 mmHg 
0.04 
0.039865517 
Wain et al, Hypertension, 2017 
Diastolic blood 
 
All 
VEGFA-[]---C6orf223 
-0.164 mmHg 
0.04 
0.000264132 
Wain et al, Hypertension, 2017 
 
Page 65 of 96
Diabetes
 Supplementary Table 7. The association of "favourable adiposity" polygenic score with measures fat distribution. 
 
 
 
14 SNPs 
7 “additional” SNPs 
 
Cohort 
Trait/disease 
Analysis 
Beta (SD) 
Se 
p-value 
Beta (SD) 
Se 
p-value 
N 
UKB 
WHR-BMIadj 
ALL 
-0.0180 
0.0006 
8.44E-191 
-0.0238 
0.0009 
2.68E-170 
449216 
 
Women 
-0.0020 
0.0000 
<E-300 
-0.0023 
0.0001 
2.36E-272 
243742 
 
Men 
0.0001 
0.0009 
0.9 
-0.0051 
0.0012 
2.88E-05 
205474 
Hip circumference-BMIadj 
ALL 
0.0152 
0.0006 
1.59E-161 
0.0164 
0.0008 
9.45E-96 
450276 
 
Women 
0.0171 
0.0008 
3.52E-109 
0.0180 
0.0011 
8.07E-62 
244400 
 
Men 
0.0130 
0.0008 
1.80E-53 
0.0145 
0.0012 
2.00E-34 
205876 
Waist circumference-
BMIadj 
ALL 
0.0029 
0.0005 
5.93E-09 
0.0011 
0.0007 
1.03E-01 
450323 
 
Women 
-0.0032 
0.0008 
3.70E-05 
-0.0056 
0.0011 
2.41E-07 
244415 
 
Men 
0.0113 
0.0008 
1.67E-40 
0.0098 
0.0012 
8.32E-17 
205908 
Published 
WHR-BMIadj 
All 
-0.0128 
0.0010 
3.03E-34 
-0.0174 
0.0015 
1.05E-31 
230000 
 
Women 
-0.0234 
0.0014 
8.86E-66 
-0.0266 
0.0019 
1.15E-42 
230000 
 
Men 
0.0012 
0.0015 
0.4 
-0.0046 
0.0022 
0.03 
230000 
Hip circumference-BMIadj 
All 
0.0125 
0.0011 
1.56E-30 
0.0122 
0.0015 
2.56E-15 
230000 
 
Women 
0.0158 
0.0014 
7.48E-30 
0.0155 
0.0020 
4.25E-15 
230000 
 
Men 
0.0086 
0.0016 
6.21E-08 
0.0078 
0.0022 
0.00046 
230000 
Waist circumference-
BMIadj 
All 
-0.0032 
0.0010 
0.002 
-0.0076 
0.0015 
2.99E-07 
230000 
 
Women 
-0.0131 
0.0013 
4.54E-23 
-0.0161 
0.0019 
1.68E-17 
230000 
 
Men 
0.0091 
0.0015 
9.22E-10 
0.0030 
0.0021 
0.15 
230000 
 
Page 66 of 96
Diabetes
 Supplementary Table 8. The association of "favourable adiposity" genetic variants with measures of abdominal fat distribution from MRI/CT 
scans. SAT: subcutaneous adipose tissue; VAT: visceral adipose tissue; LCI: lower confidence interval; UCI: upper confidence interval; P: p-
value. 
 
 
SAT 
VAT 
VATSAT ratio 
Liver fat 
Locus 
Analysis 
BETA 
(SD) 
LCI 
UCI 
P 
BETA 
(SD) 
LCI 
UCI 
P 
BETA 
(SD) 
LCI 
UCI 
P 
BETA 
(SD) 
LCI 
UCI 
P 
AEBP2---[]--
PDE3A 
All 
0.016 
-0.001 
0.033 
0.06 
0.007 
-0.01 
0.024 
0.4 
-0.013 
-0.028 
0.002 
0.098 
0.013 
-0.023 
0.049 
0.47 
ANKRD55---[]-
--MAP3K 
All 
0.005 
-0.012 
0.021 
0.6 
0.027 
0.011 
0.043 
0.001 
0.026 
0.011 
0.041 
0.001 
0.001 
-0.031 
0.034 
0.94 
CITED2---[] 
All 
0.005 
-0.011 
0.021 
0.5 
-0.013 
-0.029 
0.002 
0.098 
-0.025 
-0.039 
-0.011 
0.001 
-0.027 
-0.057 
0.002 
0.065 
[DNAH10] 
All 
0.017 
0 
0.034 
0.05 
-0.012 
-0.028 
0.005 
0.2 
-0.031 
-0.046 
-0.016 
5E-5 
-0.027 
-0.061 
0.007 
0.13 
[FAM13A] 
All 
0.023 
0.007 
0.039 
0.004 
-0.004 
-0.019 
0.012 
0.65 
-0.028 
-0.042 
-0.014 
9E-5 
-0.009 
-0.037 
0.02 
0.55 
GRB14--[]--
COBLL1 
All 
0.022 
0.007 
0.038 
0.006 
0.008 
-0.007 
0.024 
0.3 
-0.014 
-0.028 
0 
0.05 
-0.052 
-0.081 
-0.022 
0.001 
KLF14--[]---
MKLN1 
All 
0.024 
0.007 
0.04 
0.005 
0.004 
-0.012 
0.02 
0.64 
-0.02 
-0.035 
-0.005 
0.007 
-0.021 
-0.053 
0.012 
0.2 
LYPLAL1---[]-
--SLC30 
All 
0.021 
0.005 
0.037 
0.01 
-0.007 
-0.023 
0.008 
0.36 
-0.027 
-0.041 
-0.013 
0.0002 
0.008 
-0.021 
0.037 
0.6 
[MAFF] 
All 
0.019 
0.003 
0.035 
0.02 
0.022 
0.006 
0.037 
0.007 
0.003 
-0.011 
0.017 
0.64 
-0.012 
-0.043 
0.018 
0.44 
NYAP2---[]---
IRS1 
All 
0.021 
0.005 
0.037 
0.01 
-0.004 
-0.02 
0.012 
0.6 
-0.029 
-0.043 
-0.014 
8E-5 
-0.034 
-0.064 
-0.004 
0.026 
[PEPD] 
All 
0.007 
-0.009 
0.023 
0.4 
0.019 
0.004 
0.034 
0.015 
0.016 
0.002 
0.03 
0.02 
-0.011 
-0.04 
0.017 
0.43 
[PPARG] 
All 
0.026 
0.009 
0.044 
0.004 
-0.003 
-0.021 
0.014 
0.7 
-0.028 
-0.045 
-0.012 
0.001 
-0.064 
-0.106 
-0.022 
0.003 
TRIB1--[] 
All 
0.013 
-0.003 
0.029 
0.12 
-0.012 
-0.028 
0.004 
0.14 
-0.023 
-0.038 
-0.009 
0.002 
-0.072 
-0.103 
-0.04 
8E-6 
Page 67 of 96
Diabetes
 VEGFA-[]---
C6orf223 
All 
0.013 
-0.003 
0.029 
0.1 
-0.004 
-0.02 
0.011 
0.6 
-0.021 
-0.035 
-0.007 
0.003 
-0.012 
-0.033 
0.008 
0.24 
AEBP2---[]--
PDE3A 
Men 
0.013 
-0.005 
0.031 
0.145 
0.01 
-0.008 
0.028 
0.278 
-0.004 
-0.021 
0.013 
0.638 
0.011 
-0.036 
0.058 
0.648 
ANKRD55---[]-
--MAP3K 
Men 
0.002 
-0.015 
0.02 
0.8 
0.018 
0.001 
0.036 
0.042 
0.021 
0.005 
0.038 
0.012 
0.036 
-0.007 
0.079 
0.102 
CITED2---[] 
Men 
0.002 
-0.016 
0.019 
0.845 
-0.006 
-0.023 
0.011 
0.489 
-0.011 
-0.028 
0.005 
0.162 
-0.005 
-0.044 
0.033 
0.789 
[DNAH10] 
Men 
0.007 
-0.011 
0.025 
0.44 
-0.016 
-0.034 
0.002 
0.074 
-0.024 
-0.041 
-0.008 
0.004 
-0.01 
-0.056 
0.035 
0.651 
[FAM13A] 
Men 
0.008 
-0.009 
0.025 
0.348 
-0.01 
-0.027 
0.008 
0.274 
-0.015 
-0.031 
0.001 
0.062 
0.007 
-0.03 
0.045 
0.703 
GRB14--[]--
COBLL1 
Men 
0.029 
0.012 
0.046 
0.001 
0.012 
-0.005 
0.03 
0.161 
-0.014 
-0.03 
0.002 
0.088 
-0.033 
-0.071 
0.005 
0.09 
KLF14--[]---
MKLN1 
Men 
0.019 
0.002 
0.037 
0.031 
0.011 
-0.007 
0.029 
0.227 
-0.011 
-0.027 
0.006 
0.204 
-0.009 
-0.052 
0.033 
0.669 
LYPLAL1---[]-
--SLC30 
Men 
0.026 
0.009 
0.043 
0.003 
0.008 
-0.009 
0.025 
0.376 
-0.02 
-0.036 
-0.004 
0.014 
0.026 
-0.012 
0.064 
0.184 
[MAFF] 
Men 
0.02 
0.003 
0.037 
0.022 
0.023 
0.006 
0.04 
0.009 
0.005 
-0.011 
0.021 
0.544 
-0.006 
-0.044 
0.032 
0.74 
NYAP2---[]---
IRS1 
Men 
0.025 
0.008 
0.042 
0.005 
-0.004 
-0.021 
0.013 
0.658 
-0.036 
-0.052 
-0.02 
1E-5 
-0.002 
-0.042 
0.037 
0.916 
[PEPD] 
Men 
0.001 
-0.016 
0.018 
0.897 
0.018 
0.001 
0.035 
0.04 
0.02 
0.004 
0.036 
0.015 
0.004 
-0.033 
0.041 
0.844 
[PPARG] 
Men 
0.032 
0.014 
0.051 
0.001 
0.009 
-0.009 
0.028 
0.311 
-0.023 
-0.041 
-0.006 
0.01 
-0.054 
-0.109 
0 
0.051 
TRIB1--[] 
Men 
0.018 
0.001 
0.036 
0.04 
-0.005 
-0.023 
0.012 
0.558 
-0.019 
-0.035 
-0.002 
0.024 
-0.091 
-0.132 
-0.05 
2E-5 
VEGFA-[]---
C6orf223 
Men 
0.019 
0.002 
0.036 
0.031 
-0.003 
-0.02 
0.014 
0.708 
-0.03 
-0.045 
-0.014 
0.0003 
-0.001 
-0.038 
0.036 
0.958 
AEBP2---[]--
PDE3A 
Women 
0.011 
-0.008 
0.029 
0.256 
-0.001 
-0.019 
0.017 
0.907 
-0.019 
-0.036 
-0.002 
0.029 
0.015 
-0.039 
0.069 
0.584 
ANKRD55---[]-
--MAP3K 
Women 
0 
-0.018 
0.018 
0.99 
0.018 
0 
0.035 
0.05 
0.019 
0.002 
0.036 
0.025 
-0.033 
-0.083 
0.016 
0.186 
CITED2---[] 
Women 
0.007 
-0.01 
0.025 
0.423 
-0.015 
-0.032 
0.002 
0.089 
-0.029 
-0.045 
-0.013 
0.0004 
-0.05 
-0.094 
-0.006 
0.026 
[DNAH10] 
Women 
0.021 
0.003 
0.04 
0.021 
-0.002 
-0.02 
0.015 
0.782 
-0.029 
-0.045 
-0.012 
0.001 
-0.054 
-0.105 
-0.003 
0.037 
[FAM13A] 
Women 
0.026 
0.008 
0.044 
0.004 
-0.001 
-0.018 
0.016 
0.921 
-0.034 
-0.05 
-0.018 
3E-5 
-0.031 
-0.074 
0.012 
0.153 
Page 68 of 96
Diabetes
 GRB14--[]--
COBLL1 
Women 
0.008 
-0.009 
0.026 
0.351 
0 
-0.017 
0.018 
0.967 
-0.011 
-0.027 
0.005 
0.177 
-0.07 
-0.114 
-0.025 
0.002 
KLF14--[]---
MKLN1 
Women 
0.017 
-0.001 
0.035 
0.068 
-0.007 
-0.024 
0.011 
0.446 
-0.024 
-0.041 
-0.008 
0.004 
-0.017 
-0.065 
0.031 
0.483 
LYPLAL1---[]-
--SLC30 
Women 
0.007 
-0.011 
0.024 
0.459 
-0.022 
-0.039 
-0.005 
0.011 
-0.026 
-0.042 
-0.01 
0.001 
-0.01 
-0.054 
0.034 
0.649 
[MAFF] 
Women 
0.007 
-0.011 
0.024 
0.465 
0.01 
-0.007 
0.027 
0.264 
0 
-0.016 
0.016 
0.98 
-0.014 
-0.058 
0.03 
0.546 
NYAP2---[]---
IRS1 
Women 
0.011 
-0.007 
0.029 
0.238 
-0.002 
-0.019 
0.015 
0.81 
-0.012 
-0.028 
0.004 
0.145 
-0.068 
-0.114 
-0.023 
0.003 
[PEPD] 
Women 
0.01 
-0.008 
0.027 
0.277 
0.011 
-0.006 
0.028 
0.192 
0.005 
-0.01 
0.021 
0.507 
-0.026 
-0.068 
0.016 
0.233 
[PPARG] 
Women 
0.004 
-0.014 
0.023 
0.644 
-0.013 
-0.031 
0.005 
0.163 
-0.019 
-0.037 
-0.001 
0.034 
-0.074 
-0.138 
-0.009 
0.026 
TRIB1--[] 
Women 
0.003 
-0.015 
0.021 
0.711 
-0.012 
-0.029 
0.006 
0.183 
-0.017 
-0.033 
0 
0.047 
-0.051 
-0.099 
-0.004 
0.033 
VEGFA-[]---
C6orf223 
Women 
0.002 
-0.016 
0.02 
0.831 
-0.001 
-0.018 
0.016 
0.921 
-0.003 
-0.019 
0.013 
0.743 
-0.034 
-0.077 
0.009 
0.119 
 
 
Page 69 of 96
Diabetes
 Supplementary Table 9. The sensitivity analysis of the association of "favourable adiposity" polygenic score with liver fat in pre an post 
menopausal women. 
 
 
UK Biobank 
TUF 
Meta-analysis 
 
Group 
Genetic 
score 
Beta (SD) 
Se 
p-value 
N 
Beta (SD) 
Se 
p-value 
N 
Beta % 
Se 
p-value 
N 
Pdifference 
Pre 
14 SNPs 
-0.054 
0.026 
0.04 
245 
-0.059 
0.025 
0.018 
188 
-0.258 
0.018 
0.002 
433 
0.144 
Post 
-0.030 
0.010 
0.0018 
1998 
-0.010 
0.022 
0.6 
358 
-0.124 
0.009 
0.002 
2356 
Pre 
7 
“additional
” SNPs 
-0.048 
0.039 
0.22 
245 
-0.076 
0.035 
0.03 
188 
-0.294 
0.026 
0.015 
433 
0.152 
Post 
-0.028 
0.013 
0.029 
1998 
0.013 
0.033 
0.7 
358 
-0.106 
0.012 
0.06 
2356 
 
Page 70 of 96
Diabetes
 Supplementary Table 10. The sensitivity analysis of the association of "favourable adiposity" polygenic score with liver fat excluding people 
with type 2 diabetes (T2D) from the analysis. 
 
 
 
Including people with T2D 
Excluding people with T2D 
 
Genetic score 
Analysis 
Unit 
Beta 
Se 
p-value 
N 
Beta 
Se 
p-value 
N 
Pdifference 
14 SNPs 
All 
SD 
-0.09936 
0.0056 
0.0002 
5045 
-0.08832 
0.0057 
0.0007 
4823 
0.764 
Women 
SD 
-0.18492 
0.0082 
0.000001 
2648 
-0.16422 
0.0082 
0.00002 
2559 
0.698 
Men 
SD 
0.00506 
0.0076 
0.88 
2397 
0.00276 
0.0077 
0.94 
2264 
0.963 
7 “additional” SNPs 
All 
SD 
-0.10258 
0.0078 
0.004 
5045 
-0.11362 
0.0079 
0.0017 
4823 
0.829 
Women 
SD 
-0.1633 
0.0113 
0.0012 
2648 
-0.15916 
0.0113 
0.002 
2559 
0.955 
Men 
SD 
-0.02898 
0.0107 
0.55 
2397 
-0.05106 
0.0109 
0.3 
2264 
0.753 
 
Page 71 of 96
Diabetes
 Supplementary Table 11. The sensitivity analysis of the association of "favourable adiposity" polygenic score with liver fat in non-drinkers, 
moderate drinkers and heavy drinkers. LCI: lower confidence interval; UCI: upper confidence interval; P: pvalue. 
 
MEN 
WOMEN 
Group 
Beta 
LCI 
UCI 
P 
N 
Beta 
LCI 
UCI 
P 
N 
Heavy drinkers 
-0.0035 
-0.0222 
0.0152 
0.7 
1,198 
-0.0497 
-0.0827 
-0.0166 
0.003 
579 
Moderate 
drinkers 
-0.0048 
-0.0192 
0.0095 
0.5 
2,658 
-0.0406 
-0.0548 
-0.0265 
2E-8 
3,205 
Non-drinkers 
0.0448 
-0.0237 
0.1133 
0.2 
146 
-0.0084 
-0.0649 
0.0480 
0.769 
253 
 
Page 72 of 96
Diabetes
 Supplementary Table 12. Inclusion of adiponectin, SHBG and ALT in the multivariate analysis increases the power of metaCCA to detect 
"favourable adiposity" variants. 
RSID 
Gene context 
Metacca p-
value  
(7 traits) 
MetaCCA p-value  
(excluding adiponectin, SHBG 
and ALT) 
MetaCCA p-value  
(excluding adiponectin and SHBG) 
rs2943653 
NYAP2---[]---IRS1 
2E-43 
7E-22 
3E-32 
rs13389219 
GRB14--[]--COBLL1 
5E-41 
4E-21 
3E-26 
rs2980888 
TRIB1--[] 
1E-35 
2E-33 
6E-21 
rs11118306 
LYPLAL1---[]---SLC30A10 
3E-21 
9E-13 
3E-13 
rs2276936 
[FAM13A] 
3E-20 
9E-9 
5E-14 
rs972283 
KLF14--[]---MKLN1 
1E-19 
9E-13 
1E-26 
rs7133378 
[DNAH10] 
2E-17 
1E-6 
4E-13 
rs2267373 
[MAFF] 
8E-14 
1E-11 
3E-8 
rs40271 
ANKRD55---[]---MAP3K1 
1E-12 
1E-9 
1E-8 
rs7258937 
[PEPD] 
5E-12 
0.0002 
4E-7 
rs998584 
VEGFA-[]---C6orf223 
5E-11 
0.0002 
2E-6 
rs1801282 
[PPARG] 
2E-10 
3E-5 
3E-7 
rs632057 
CITED2---[] 
3E-10 
1E-5 
8E-9 
rs11045172 
AEBP2---[]--PDE3A 
4E-9 
4E-6 
0.008 
 
Page 73 of 96
Diabetes
 Supplementary figure 1. Study design. 
Page 74 of 96
Diabetes
  
Step 2. Multivariate GWAS of metabolic 
biomarkers
Step 1. GWAS of body fat %
Step 3. Identify a cluster of SNPs 
associated with “favourable adiposity”
Step 4. Test “favourable adiposity” SNPs 
against risk of type 2 diabetes, hypertension 
and heart disease
Step 5. Test the effect of “favourable 
adiposity” SNPs on body fat distribution
SF1
Page 75 of 96
Diabetes
 Supplementary figure 2. Manhattan plot of  variants associated with a Bio-impedance measures of body fat % in UK Biobank study.  
Page 76 of 96
Diabetes
  
PRMT6--[]--NTNG1
LYPLAL1---[]---SLC30A10
[GALNT2]
MYCN---[]---FAM49A
ADCY3-[]--DNAJC27
[PPP1R21]
[ACMSD]
GRB14--[]--COBLL1
NYAP2---[]---IRS1
[PPARG]
[STAG1]
[FAM13A]
ANKRD55---[]---MAP3K1
VEGFA-[]---C6orf223
CITED2---[]
[POM121C]
KLF14--[]---MKLN1
TRIB1--[]
[TET1]
[TCF7L2]
CELF1--[]--PTPMT1
AEBP2---[]--PDE3A
[DNAH10]
PCDH17---[]---DIAPH3
[RORA]
[FTO]
[ZZEF1]
[TNFSF12-TNFSF13]
ZBTB7C---[]---CTIF
[PEPD]
[KIAA1755]
[MAFF]
[ACO2
SF2
Page 77 of 96
Diabetes
 Supplementary figure 3. We use hierarchical clustering approach to narrow down the list to ones showing a pattern of “favourable adiposity”: 
alleles associated with higher body fat % being generally correlated with higher HDL-C, higher SHBG, higher adiponectin, lower fasting insulin, 
lower triglycerides and lower alanine transaminase. The red box illustrates the “favourable adiposity” variants which cluster together 94% of the 
time. 
Page 78 of 96
Diabetes
  
Page 79 of 96
Diabetes
 Supplementary figure 4. The effect of 7 previously known “favourable adiposity” variants (a) and 7 “additional” variants (b) on body fat % 
(data from UK Biobank), metabolic biomarkers (data from published GWASs), measures of abdominal adipose tissue (data from meta-analysis 
of 5 studies) and cardiometabolic disease outcome (data from UK Biobank). The x-axis is the effect size for “favourable adiposity” allele. The 
effect sizes are in SD for body fat % and measures of abdominal fat, log transformed for adiponectin, HDL, Triglycerides, alanine transaminase 
(ALT) and fasting insulin, nmol/L for sex hormone binding globulin (SHBG) and log(OR) for disease outcomes.  
Page 80 of 96
Diabetes
  
PPARG
PEPD
FAM13A
ANKRD55
GRB14
IRS1
LYPLAL1
Body fat % all
females
males
Adiponectin
HDL-C
SHBG
ALT
Fasting insulin
Triglycerides
Subcutaneous fat all
females
males
Viscera fat all
females
males
VATSAT ratio all
females
males
Liver fat all
females
males
Type 2 diabetes all
females
males
Heart disease all
females
males
Hypertension all
females
males
-0.08          0            0.08
-0.08          0            0.08
-0.08          0            0.08
-0.08          0            0.08
-0.08          0            0.08
-0.08          0            0.08
-0.08          0            0.08
SF4-a
Page 81 of 96
Diabetes
  
TRIB1
KLF14
MAFF
CITED2
DNAH10
VEGFA
AEBP2
-0.08          0            0.08
-0.08          0            0.08
-0.08          0            0.08
-0.08          0            0.08
-0.08          0            0.08
-0.08          0            0.08
-0.08          0            0.08
Body fat % all
females
males
Adiponectin
HDL-C
SHBG
ALT
Fasting insulin
Triglycerides
Subcutaneous fat all
females
males
Viscera fat all
females
males
VATSAT ratio all
females
males
Liver fat all
females
males
Type 2 diabetes all
females
males
Heart disease all
females
males
Hypertension all
females
males
SF4-b
Page 82 of 96
Diabetes
 Supplementary figure 1. Study design. 
Page 83 of 96
Diabetes
 Step 2. Multivariate GWAS of metabolic 
biomarkers
Step 1. GWAS of body fat %
Step 3. Identify a cluster of SNPs 
associated with “favourable adiposity”
Step 4. Test “favourable adiposity” SNPs 
against risk of type 2 diabetes, hypertension 
and heart disease
Step 5. Test the effect of “favourable 
adiposity” SNPs on body fat distribution
SF1
Page 84 of 96
Diabetes
 Supplementary figure 2. Manhattan plot of  variants associated with a Bio-impedance measures of body fat 
% in UK Biobank study. 
Page 85 of 96
Diabetes
 PRMT6--[]--NTNG1
LYPLAL1---[]---SLC30A10
[GALNT2]
MYCN---[]---FAM49A
ADCY3-[]--DNAJC27
[PPP1R21]
[ACMSD]
GRB14--[]--COBLL1
NYAP2---[]---IRS1
[PPARG]
[STAG1]
[FAM13A]
ANKRD55---[]---MAP3K1
VEGFA-[]---C6orf223
CITED2---[]
[POM121C]
KLF14--[]---MKLN1
TRIB1--[]
[TET1]
[TCF7L2]
CELF1--[]--PTPMT1
AEBP2---[]--PDE3A
[DNAH10]
PCDH17---[]---DIAPH3
[RORA]
[FTO]
[ZZEF1]
[TNFSF12-TNFSF13]
ZBTB7C---[]---CTIF
[PEPD]
[KIAA1755]
[MAFF]
[ACO2]
SF2
Page 86 of 96
Diabetes
 Supplementary figure 3. We use hierarchical clustering approach to narrow down the
list to ones showing a pattern of “favourable adiposity”: alleles associated with higher
body fat % being generally correlated with higher HDL-C, higher SHBG, higher
adiponectin, lower fasting insulin, lower triglycerides and lower alanine transaminase.
The red box illustrates the “favourable adiposity” variants which cluster together 94%
of the time.
Page 87 of 96
Diabetes
 Body fat%
SHBG
Adiponectin
HDL-C
ALT
Fasting insulin - BMIadj
Triglycerides
beta_triglycerides
beta_fibmiadj
beta_ALT
beta_hdlc
beta_adiponectin
beta_shbg
beta_bfp
[STAG1]
[GALNT2]
CELF1−−[]−−PTPMT1
ADCY3−[]−−DNAJC27
[ACMSD]
[FTO]
[PPP1R21]
PRMT6−−[]−−NTNG1
[ZZEF1]
MYCN−−−[]−−−FAM49A
ZBTB7C−−−[]−−−CTIF
[KIAA1755]
[TET1]
[POM121C]
[TCF7L2]
PCDH17−−−[]−−−DIAPH3
[RORA]
[ACO2]
[TNFSF12−TNFSF13]
TRIB1−−[]
KLF14−−[]−−−MKLN1
[MAFF]
ANKRD55−−−[]−−−MAP3K1
[PPARG]
GRB14−−[]−−COBLL1
NYAP2−−−[]−−−IRS1
CITED2−−−[]
[PEPD]
[FAM13A]
LYPLAL1−−−[]−−−SLC30A10
AEBP2−−−[]−−PDE3A
VEGFA−[]−−−C6orf223
[DNAH10]
Positive 
correlation
Negative
correlation
SF3
Page 88 of 96
Diabetes
 Supplementary figure 4. The effect of 7 previously known “favourable adiposity”
variants (a) and 7 “additional” variants (b) on body fat % (data from UK Biobank),
metabolic biomarkers (data from published GWASs), measures of abdominal adipose
tissue (data from meta-analysis of 5 studies) and cardiometabolic disease outcome
(data from UK Biobank). The x-axis is the effect size for “favourable adiposity” allele.
The effect sizes are in SD for body fat % and measures of abdominal fat, log
transformed for adiponectin, HDL, Triglycerides, alanine transaminase (ALT) and
fasting insulin, nmol/L for sex hormone binding globulin (SHBG) and log(OR) for
disease outcomes.
Page 89 of 96
Diabetes
 PPARG
PEPD
FAM13A
ANKRD55
GRB14
IRS1
LYPLAL1
Body fat % all
females
males
Adiponectin
HDL-C
SHBG
ALT
Fasting insulin
Triglycerides
Subcutaneous fat all
females
males
Viscera fat all
females
males
VATSAT ratio all
females
males
Liver fat all
females
males
Type 2 diabetes all
females
males
Heart disease all
females
males
Hypertension all
females
males
-0.08          0            0.08
-0.08          0            0.08
-0.08          0            0.08
-0.08          0            0.08
-0.08          0            0.08
-0.08          0            0.08
-0.08          0            0.08
SF4-a
Page 90 of 96
Diabetes
 TRIB1
KLF14
MAFF
CITED2
DNAH10
VEGFA
AEBP2
-0.08          0            0.08
-0.08          0            0.08
-0.08          0            0.08
-0.08          0            0.08
-0.08          0            0.08
-0.08          0            0.08
-0.08          0            0.08
Body fat % all
females
males
Adiponectin
HDL-C
SHBG
ALT
Fasting insulin
Triglycerides
Subcutaneous fat all
females
males
Viscera fat all
females
males
VATSAT ratio all
females
males
Liver fat all
females
males
Type 2 diabetes all
females
males
Heart disease all
females
males
Hypertension all
females
males
SF4-b
Page 91 of 96
Diabetes
 Supplementary Table 11. The sensitivity analysis of the association of "favourable adiposity" polygenic score with liver fat in non-drinkers, moderate drinkers and heavy drinkers.
Beta
LCI
UCI
P
Heavy drinkers
-0.0034659 -0.0221768 0.015245
0.716
Moderate drinkers
-0.0048209 -0.0191789 0.0095372
0.51
Non-drinkers
0.0448014
-0.0237114 0.1133142
0.198
MEN
Page 92 of 96
Diabetes
 . The sensitivity analysis of the association of "favourable adiposity" polygenic score with liver fat in non-drinkers, moderate drinkers and heavy drinkers.
N
Beta
LCI
UCI
P
N
1,198
-0.0496669 -0.0827381 -0.0165957 0.003
579
2,658
-0.0406346 -0.0547673 -0.0265018 2.00E-08
3,205
146
-0.008421
-0.0648655 0.0480235
0.769
253
WOMEN
Page 93 of 96
Diabetes
 . The sensitivity analysis of the association of "favourable adiposity" polygenic score with liver fat in non-drinkers, moderate drinkers and heavy drinkers.
Page 94 of 96
Diabetes
 Supplementary Table 12. Inclusion of adiponectin, SHBG and ALT in the multivariate analysis increases the power of metaCCA to detect "favourable adiposity" variants.
RSID 
Gene context
Metacca p-value 
(7 traits)
rs2943653
NYAP2---[]---IRS1
2.00E-43
rs13389219
GRB14--[]--COBLL1
5.00E-41
rs2980888
TRIB1--[]
1.00E-35
rs11118306
LYPLAL1---[]---SLC30A10 3.00E-21
rs2276936
[FAM13A]
3.00E-20
rs972283
KLF14--[]---MKLN1
1.00E-19
rs7133378
[DNAH10]
2.00E-17
rs2267373
[MAFF]
8.00E-14
rs40271
ANKRD55---[]---MAP3K1 1.00E-12
rs7258937
[PEPD]
5.00E-12
rs998584
VEGFA-[]---C6orf223
5.00E-11
rs1801282
[PPARG]
2.00E-10
rs632057
CITED2---[]
3.00E-10
rs11045172
AEBP2---[]--PDE3A
4.00E-09
Page 95 of 96
Diabetes
 . Inclusion of adiponectin, SHBG and ALT in the multivariate analysis increases the power of metaCCA to detect "favourable adiposity" variants.
MetaCCA p-value 
(excluding adiponectin, SHBG and 
MetaCCA p-value 
(excluding adiponectin and SHBG)
7.00E-22
3.00E-32
4.00E-21
3.00E-26
2.00E-33
6.00E-21
9.00E-13
3.00E-13
9.00E-09
5.00E-14
9.00E-13
1.00E-26
1.00E-06
4.00E-13
1.00E-11
3.00E-08
1.00E-09
1.00E-08
0.0002
4.00E-07
0.0002
2.00E-06
3.00E-05
3.00E-07
1.00E-05
8.00E-09
4.00E-06
0.008
Page 96 of 96
Diabetes
 . Inclusion of adiponectin, SHBG and ALT in the multivariate analysis increases the power of metaCCA to detect "favourable adiposity" variants.
Page 97 of 96
Diabetes
